

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

<b>Original Issue Date (Created):</b>	August 1, 2009
<b>Most Recent Review Date (Revised):</b>	September 24, 2013
<b>Effective Date:</b>	November 1, 2013

## I. POLICY

Preauthorization is required for Thrombopoietic Growth Factors.

Requests for Romiplostim (Nplate™) and Oprelvekin (Neumega®) must be accompanied by a completed preauthorization form prior to treatment.

### **Romiplostim (Nplate™)**

Romiplostim (Nplate™) is approved by the U.S. Food and Drug Administration (FDA) for the following indication:

Romiplostim (Nplate™) is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

### **Pediatric Use**

The safety and effectiveness in pediatric patients (< 18 years) have not been established.

### **Initial Therapy for Romiplostim (Nplate™)**

**Note:** Initial therapy may be authorized for a maximum duration of twelve (12) weeks and to a maximum dosage of 250 mcgs/week. Dosages above 250 mcgs require reauthorization per the criteria for maintenance therapy below. A completed preauthorization form must be submitted with the request.

Romiplostim (Nplate™) for the treatment of thrombocytopenia may be considered **medically necessary** when **ALL** of the following are met:

- Patient has documented diagnosis of relapsed/refractory chronic (> 6 months) immune (idiopathic) thrombocytopenia purpura (ITP); and
- Patient has a baseline platelet count  $\leq 30,000 /\mu\text{L}$  or  $30,000/\mu\text{L}$  to  $50,000/\mu\text{L}$  with significant mucous membrane bleeding or bleeding risk factors; and

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

- Romiplostim (Nplate™) has been prescribed by, or in consultation with, a hematologist; and
- Patient has not responded adequately to, or cannot tolerate, a one (1) month trial of oral eltrombopag (Promacta™); and
- Patient has had an insufficient response to either splenectomy or one of the following medications:
  - Corticosteroids
    - o Prednisone at a dose of at least 1 mg/kg daily for at least three (3) weeks; or
    - o Dexamethasone at a dose of 40 mg/day for at least four (4) days.
  - Immunoglobulins for at least a one (1) month trial.

**Maintenance Therapy for Romiplostim (Nplate™)**

**Note:** Maintenance therapy may be authorized for a maximum duration of six (6) months. Consideration of additional authorization requires documentation of weekly platelet counts and corresponding romiplostim (Nplate™) doses for six (6) to eight (8) weeks prior to the current request. A completed preauthorization form must be submitted with the request.

**Romiplostim (Nplate™)** for the continued treatment of thrombocytopenia may be considered **medically necessary** when **ALL** of the following are met:

- Patient has a current platelet count of 40,000/μL to 100,000/μL; (indicating that ITP has not remitted).
- Patient is responding to therapy as evidenced by increased platelet counts.
- Requests for doses > 250 mcgs require evidence of a platelet count of < 30,000/μL or 30,000/μL to 50,000/μL with significant mucous membrane bleeding or bleeding risk factors. Reauthorizations for doses > 250 mcgs will be to a maximum of the next 250 mcg increment (i.e. up to 500 mcgs, up to 750 mcgs, etc.).

Administration of romiplostim (Nplate™) for any indication (e.g. chemotherapy-induced thrombocytopenia, myelodysplastic syndrome) other than as described in the policy statement is considered **investigational** as there is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure.

Administration of romiplostim (Nplate™) as an attempt to normalize platelet counts or when the platelet count is ≥ 400,000/μL is considered **not medically necessary**.

Administration of romiplostim (Nplate™) is considered not medically necessary if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after four (4) weeks of therapy at the maximum weekly dose of 10 mcg/kg.

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

**Oprelvekin (Neumega®)**

Oprelvekin (Neumega®) is approved by the U.S. Food and Drug Administration (FDA) for the following indication:

Neumega is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia. Neumega is not indicated following myeloablative chemotherapy.

**Pediatric Use**

The safety and effectiveness of Neumega have not been established in pediatric patients.

**Initial Therapy for Oprelvekin (Neumega®)**

**Oprelvekin (Neumega®)** for the treatment of thrombocytopenia may be considered **medically necessary** when **ALL** of the following are met:

- Patient has a documented diagnosis of nonmyeloid cancer; and
- Oprelvekin (Neumega®) has been prescribed in consultation with an oncologist; and
- When administered for **ANY ONE** of the following:
  - To reduce the need for platelet transfusions following myelosuppressive chemotherapy
  - To reduce the high risk for severe thrombocytopenia (platelet count less than 20,000/ $\mu$ L) in patients who experienced severe thrombocytopenia in the previous chemotherapy cycle.

**Maintenance Therapy for Oprelvekin (Neumega®)**

**Oprelvekin (Neumega®)** for the treatment of thrombocytopenia may be considered **medically necessary** when **ALL** of the following are met:

- The post-nadir platelet count is  $<50,000/\mu$ L; and
- Dosing does not exceed 21 days per treatment course.

Administration of oprelvekin (Neumega®) for any indication other than as described in the policy statement is considered investigational as there is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure.

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

Administration of oprelvekin (Neumega®) beyond twenty-one (21) days per treatment course is considered not medically necessary.

Administration of oprelvekin (Neumega®) when the platelet count is  $\geq 50,000/\mu\text{L}$  is **considered not medically necessary**.

Concomitant administration of thrombopoietic growth factors is considered **investigational**, as there is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure.

***Cross-references***

MP-2.110 Rituximab (Rituxan®)

MP-2.023 Immune Globulin

MP-4.024 Pheresis and Apheresis Therapy

**II. PRODUCT VARIATIONS**

*[N] = No product variation, policy applies as stated*

*[Y] = Standard product coverage varies from application of this policy, see below*

[N] PPO

[N] SpecialCare

[N] HMO

[N] POS

[N] Capital Cares for Kids

[N] Indemnity

[N] SeniorBlue HMO(see note)

[Y] FEP PPO\*\*

[N] SeniorBlue PPO(see note)

Note: “FDA approved drugs used for indications other than what is indicated on the official label may be covered under Medicare if determined that the use is medically accepted, taking into consideration the major drug compendia, authoritative medical literature and/or accepted standards of medical practice.” Refer to Medicare Benefit Policy Manual (100-2, Chapter 15, Section 50.4.2- Unlabeled Use of Drug).”

<http://www.cms.gov/manuals/Downloads/bp102c15.pdf>

Note:“Off-label use of FDA approved drugs and biologicals used in an anti-cancer chemotherapeutic regimen for medically accepted indications may be covered under Medicare if the indications are supported in either one or more Medicare recognized compendia or in peer-reviewed literature. Refer to Medicare Benefit Policy Manual (100-2, Chapter 15, Section 50.4.5- Off-Label Use of Drugs and Biologicals in an Anti-Cancer Chemotherapeutic Regimen) for the compendia list.”

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

<http://www.cms.gov/manuals/Downloads/bp102c15.pdf>

The FEP program dictates that all drugs, devices or biological products approved by the U.S. Food and Drug Administration (FDA) may not be considered investigational. Therefore, FDA-approved drugs, devices or biological products may be assessed on the basis of medical necessity.

**III. DESCRIPTION/BACKGROUND**

Thrombopoietic growth factors stimulate the production of platelets. Platelet counts of 150,000 to 450,000 per microliter (µL) are considered normal in adults. Thrombocytopenia is an abnormal decrease in the number of platelets due to decreased production and/or increased platelet destruction. Patients with thrombocytopenia are at increased risk of spontaneous bleeding and hemorrhage. Many clinical conditions (e.g. infectious disease processes, autoimmune conditions, hereditary factors, malignancies, drug-induced, etc.) can result in thrombocytopenia. Idiopathic thrombocytopenic purpura (ITP) and chemotherapy-induced thrombocytopenia are two examples.

ITP is an autoimmune bleeding disorder characterized by increased platelet destruction and, in some cases, inadequate platelet production. With ITP, platelet counts are below 150,000 per microliter (µL). ITP that lasts longer than 6 months is defined as chronic. First-line treatments of ITP include corticosteroids and intravenous immunoglobulins. Second-line treatment options include rituximab, splenectomy and other immune suppressive agents. Spontaneous remission of chronic ITP occurs infrequently; approximately 5% of patients had an apparent spontaneous recovery after failing to respond completely to glucocorticoid, splenectomy, and any subsequent therapy.

Chemotherapy-induced thrombocytopenia is the most common cause of thrombocytopenia. Risk factors for chemotherapy-induced thrombocytopenia include some chemotherapeutic agents, types of cancers, radiation therapy, bone marrow involvement and prior treatment for malignancy.

Federal Drug Administration (FDA) approved subcutaneously administered thrombopoietic growth factors include thrombopoietins (TPO) such as romiplostim (Nplate™) and interleukins (IL-11 [oprelvekin, Neumega®]). The FDA approved the first oral TPO (eltrombopag, [Promacta™]) in November 2008. Clinical trials are in progress for additional thrombopoietic agents and expanded indications for FDA approved agents.

**Thrombopoietins**

Romiplostim (Nplate™) is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

(ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

FDA labeling recommends that romiplostim (Nplate™) should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding and should not be used in an attempt to normalize platelet counts. In general, ITP treatment guidelines indicate that treatment (initial or maintenance) is not required in patients with platelet counts >20,000/μL to 30,000/μL. However, treatment (initial or maintenance) is indicated in those with platelet counts <50,000/μL when there is significant mucous membrane bleeding or bleeding risk factors (e.g., peptic ulcer disease, uncontrolled hypertension, cerebrovascular disease) or disorders requiring treatment with antiplatelet agents or anticoagulants, or the need for surgery or other invasive procedures.

The initial dose of romiplostim (Nplate™) is 1 mcg/kg once weekly as a subcutaneous injection. The weekly dose is adjusted by increments of 1 mcg/kg to achieve and maintain an adequate platelet count as necessary to reduce the risk for bleeding. Dosing increments may be adjusted to minimize wastage. The weekly maximum dose is 10 mcg/kg. The FDA label recommends dosing adjustments as follows: if the platelet count is < 50,000/μL, increase the dose by 1 mcg/kg; if the platelet count is > 200,000/μL for 2 consecutive weeks, reduce the dose by 1 mcg/kg; if the platelet count is > 400,000/μL do not dose; after the platelet count has fallen to < 200,000/μL, resume Nplate™ at a dose reduced by 1 mcg/kg.

Romiplostim (Nplate™) should be discontinued if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 weeks of therapy at the maximum weekly dose of 10 mcg/kg.

Romiplostim (Nplate™) may be used with other medical ITP therapies such as corticosteroids and immunoglobulins.

Romiplostim (Nplate™) is available in 250 mcg or 500 mcg single dose vials that must be used within 24 hours of reconstitution.

**Interleukin eleven (IL-11)**

Oprelvekin (Neumega®) is a thrombopoietic growth factor that induces megakaryocyte maturation resulting in increased platelet production. IL-11 is a member of a family of human growth factors which includes human growth hormone, granulocyte colony stimulating factor (G-CSF), and other growth factors.

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

Oprelvekin (Neumega®) is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia. Oprelvekin (Neumega®) is not indicated following myeloablative chemotherapy.

The recommended dose of oprelvekin (Neumega®) in adults without severe renal impairment is 50 mcg/kg given once daily as a subcutaneous injection. Dosing should be initiated six to 24 hours after the completion of chemotherapy and should be continued until the post-nadir platelet count is  $\geq 50,000/\mu\text{L}$ . Dosing beyond 21 days per treatment course is not recommended. Treatment with oprelvekin (Neumega®) should be discontinued at least two days before starting the next planned cycle of chemotherapy. Oprelvekin (Neumega®) may be administered by a healthcare provider or self-administered by patients who have had adequate training.

**Safety Information for Oprelvekin (Neumega®)**

Current Oprelvekin (Neumega®) prescribing information includes the following FDA required “Black Box Warning” due to the risk of Allergic reactions including Anaphylaxis: Neumega® has caused allergic or hypersensitivity reactions, including anaphylaxis. Administration of Neumega® should be permanently discontinued in any patient who develops an allergic or hypersensitivity reaction.

**IV. RATIONALE**

Neumega

Two randomized, double-blind, placebo-controlled trials in adults studied Neumega for the prevention of severe thrombocytopenia following single or repeated sequential cycles of various myelosuppressive chemotherapy regimens.

**Study in Patients with Prior Chemotherapy-Induced Thrombocytopenia**

One study evaluated the effectiveness of Neumega in eliminating the need for platelet transfusions in patients who had recovered from an episode of severe chemotherapy-induced thrombocytopenia (defined as a platelet count  $\leq 20,000/\mu\text{h}$ ), and were to receive one additional cycle of the same chemotherapy without dose reduction. Patients had various underlying non-myeloid malignancies, and were undergoing dose-intensive chemotherapy with a variety of regimens. Patients were randomized to receive Neumega at a dose of 25 mcg/kg or 50 mcg/kg, or placebo. The primary endpoint was whether the patient required one or more platelet transfusions in the subsequent chemotherapy cycle. Ninety-three patients were randomized. Five patients withdrew from the study prior to receiving the study drug. As a result, eighty-eight

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

patients were included in a modified intent-to-treat analysis. The results for the Neumega 50 mcg/kg and placebo groups are summarized in Table 1. The placebo group includes one patient who underwent chemotherapy dose reduction and who avoided platelet transfusions.

**TABLE 1 STUDY RESULTS**

	Placebo n=30	Neumega 50 mcg/kg n=29
Number (%) of patients avoiding platelet transfusion	2 (7%)	8 (28%)
Number (%) of patients requiring platelet transfusion	28 (93%)	21 (72%)
Median (mean) number of platelet transfusion events	2.5 (3.3)	1 (2.2)

In the primary efficacy analysis, more patients avoided platelet transfusion in the Neumega 50 mcg/kg arm than in the placebo arm (p = 0.04, Fisher's Exact test, 2-tailed). The difference in the proportion of patients avoiding platelet transfusions in the Neumega 50 mcg/kg and placebo groups was 21% (95% confidence interval, 2%-40%). The results observed in patients receiving 25 mcg/kg of Neumega were intermediate between those of the placebo and the 50 mcg/kg groups.

**Study in Patients Receiving Dose-Intensive Chemotherapy**

A second study evaluated the effectiveness of Neumega in eliminating platelet transfusions over two dose-intensive chemotherapy cycles in breast cancer patients who had not previously experienced severe chemotherapy-induced thrombocytopenia. All patients received the same chemotherapy regimen (cyclophosphamide 3,200 mg/m<sup>2</sup> and doxorubicin 75 mg/m<sup>2</sup>). All patients received concomitant filgrastim (G-CSF) in all cycles. The patients were stratified by whether or not they had received prior chemotherapy, and randomized to receive Neumega 50 mcg/kg or placebo. The primary endpoint was whether or not a patient required one or more platelet transfusions in the two study cycles. Seventy-seven patients were randomized. Thirteen patients failed to complete both study cycles. Seventy-seven patients were randomized. Thirteen in for the primary endpoint. The results of this trial are summarized in [Table 2](#).

**TABLE 2 STUDY RESULTS**

	<b>Overall n=77</b>		<b>No Prior Chemotherapy n=54</b>		<b>Prior Chemotherapy n=23</b>	
	<b>Placebo</b>	<b>Neumega</b>	<b>Placebo</b>	<b>Neumega</b>	<b>Placebo</b>	<b>Neumega</b>

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

	<b>n=37</b>	<b>n=40</b>	<b>n=27</b>	<b>n=27</b>	<b>n=10</b>	<b>n=13</b>
Number (%) of patients avoiding platelet transfusion	15 (41%)	26 (65%)	14 (52%)	19 (70%)	1 (10%)	7 (54%)
Number (%) of patients requiring platelet transfusion	16 (43%)	12 (30%)	9 (33%)	7 (26%)	7 (70%)	5 (38%)
Number (%) of patients not evaluable	6 (16%)	2 (5%)	4 (15%)	1 (4%)	2 (20%)	1 (8%)

This study showed a trend in favor of Neumega, particularly in the subgroup of patients with prior chemotherapy. Open-label treatment with Neumega has been continued for up to four consecutive chemotherapy cycles without evidence of any adverse effect on the rate of neutrophil recovery or red blood cell transfusion requirements. Some patients continued to maintain platelet nadirs >20,000/cell transfusion requirements. Some patients continued to the need for transfusions, chemotherapy dose reduction, or changes in treatment schedules. Platelet activation studies done on a limited number of patients showed no evidence of abnormal spontaneous platelet activation, or an abnormal response to ADP. In an unblinded, retrospective analysis of the two placebo-controlled studies, 19 of 69 patients (28%) receiving Neumega 50 mcg/kg and 34 of 67 patients (51%) receiving placebo reported at least one hemorrhagic adverse event which involved bleeding.

**Study in Patients Following Myeloablative Chemotherapy**

In a randomized, double-blind, placebo-controlled, Phase 2 study conducted in 80 women with high-risk breast cancer who received 0 (n=26), 25 mcg/kg (n=28), or 50 mcg/kg (n=26) Neumega following myeloablative chemotherapy and autologous bone marrow transplantation, the incidence of platelet transfusions and time to neutrophil and platelet engraftment were similar in the Neumega and placebo-treated arms. The study showed a statistically significant increased incidence in edema, conjunctival bleeding, hypotension, and tachycardia in patients receiving Neumega as compared to placebo. In long term follow-up of patients, the distribution of survival and progression-free survival times was similar between patients randomized to Neumega therapy and those randomized to receive placebo

**Romiplostim (Nplate™)**

FDA approval of Nplate was based on the results of two double-blind, placebo-controlled clinical studies and an open-label extension study.

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

**Studies One and Two**

These studies enrolled subjects with chronic ITP who had completed at least one prior treatment and had a platelet count of less than or equal to 30 x 10<sup>9</sup>/L prior to study entry. The subjects were randomized to 24 weeks of single weekly SC injections of Nplate (1 mcg/kg subcutaneous [SC]) or placebo. Individual dose adjustments were made to maintain platelet counts (50 x 10<sup>9</sup>/L to 200 x 10<sup>9</sup>/L). Subjects already receiving ITP medical therapies at a constant dosing schedule were allowed to continue receiving these medical treatments throughout the studies.

**Study One**

This study evaluated subjects who had not undergone a splenectomy. Overall, the median platelet count was 19 x 10<sup>9</sup>/L at study entry. During the study, the median weekly Nplate dose was 2 mcg/kg.

**Study Two**

This study evaluated subjects who had undergone a splenectomy. Overall, the median platelet count was 14 x 10<sup>9</sup>/L at study entry. During the study, the median weekly Nplate dose was 3 mcg/kg.

**Results**

A durable platelet response was the achievement of a weekly platelet count greater than or equal to 50 x 10<sup>9</sup>/L for any 6 of the last 8 weeks of the 24-week treatment period in the absence of rescue medication at any time. A transient platelet response was the achievement of any weekly platelet counts greater than or equal to 50 x 10<sup>9</sup>/L for any 4 weeks during the treatment period without a durable platelet response. An overall platelet response was the achievement of either a durable or a transient platelet response.

*Results from Study One*

Durable Platelet Response: 61% for Nplate versus 5% for placebo  
 Overall Platelet Response: 88% for Nplate versus 14% for placebo  
 Number of Weeks With Platelet Counts > 50 x 10<sup>9</sup>/L, average: 15 weeks for Nplate versus 1 week with placebo  
 Requiring Rescue Therapy: 20% in the Nplate group compared to 62% in the placebo group

*Results from Study Two*

Durable Platelet Response: 38% for Nplate compared to 0% for placebo  
 Overall Platelet Response: 79% for Nplate compared to 0% for placebo  
 Number of Weeks With Platelet Counts > 50 x 10<sup>9</sup>/L, average: 12 weeks in the Nplate arm

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

compared to 0 weeks for the placebo arm  
 Requiring Rescue Therapy: 26% in the Nplate arm compared to 57% in the placebo arm.

In both studies, nine subjects reported a serious bleeding event. Bleeding events that were grade 2 severity or higher occurred in 15% of subjects treated with Nplate and 34% of those treated with placebo.

**Extension Study**

Subjects who had participated in either Study 1 or Study 2 were withdrawn from study medications. If platelet counts subsequently decreased to less than or equal to 50 x 10<sup>9</sup>/L, the patients were allowed to receive Nplate in an open-label extension study with weekly dosing based on platelet counts. Following Nplate discontinuation in Studies 1 and 2, seven patients maintained platelet counts of greater than 50 x 10<sup>9</sup>/L. Among 100 subjects who subsequently entered the extension study, platelet counts were increased and sustained regardless of whether they had received Nplate or placebo in the prior placebo-controlled studies. The majority of subjects reached a median platelet count of 50 x 10<sup>9</sup>/L after receiving one to three doses of Nplate, and these platelet counts were maintained throughout the remainder of the study with a median duration of Nplate treatment of 60 weeks and a maximum duration of 96 weeks.

**V. DEFINITIONS**

**AGONIST** refers to a drug that has affinity for and stimulates physiologic activity at cell receptors normally stimulated by naturally occurring substances.

**IDIOPATHIC** refers to conditions without a known cause.

**IMMUNOGLOBULINS** are plasma proteins made up of polypeptide chains. They are one of the primary mechanisms for protection against disease.

**MYELOSUPPRESSIVE** refers to inhibition of bone marrow function.

**NADIR** refers to the lowest concentration of blood cells found after taking a drug that suppresses the bone marrow.

**NONMYELOID** refers to not being, involving, or affecting bone marrow.

**PLATELET** refers to the smallest cells in the blood, essential for coagulation and for hemostasis.

**V. BENEFIT VARIATIONS**

The existence of this medical policy does not mean that this service is a covered benefit under the member's contract. Benefit determinations should be based in all cases on the applicable contract language. Medical policies do not constitute a description of benefits. A member's individual or group customer benefits govern which services are covered, which are excluded, and which are subject to benefit limits and which require

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

preauthorization. Members and providers should consult the member’s benefit information or contact Capital for benefit information.

**VI. DISCLAIMER**

*Capital’s medical policies are developed to assist in administering a member’s benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member’s benefit information, the benefit information will govern. Capital considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.*

**VII. REFERENCES**

*Amgen. Nplate™ (romiplostim (Nplate)). [Website]: <http://www.nplate.com/>. Accessed July 24, 2013.*

*Bussel JB, Cheng G, Saleh MN. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007 Nov 29;357(22):2237-47.*

*Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2008 Nov 3.*

*Centers for Medicare and Medicaid Services (CMS) Medicare Benefit Policy Manual. Publication 100-02. Chapter 15. Section 50.4.5. Off-Label Use of Anti-Cancer Drugs and Biologicals. [Website]: <http://www.cms.gov/manuals/Downloads/bp102c15.pdf>. Accessed July 24, 2013.*

*Centers for Medicare and Medicaid Services (CMS) Medicare Benefit Policy Manual. Publication 100-02. Chapter 15. Section 50.4.2. Unlabeled Use of Drug. Effective 10/01/03. [Website]: <http://www.cms.gov/manuals/Downloads/bp102c15.pdf>. Accessed July 24, 2013.*

*Centers for Medicare and Medicaid Services (CMS) Medicare Benefit Policy Manual. Publication 100-02. Chapter 15. Sections 50, 50.4.1, 50.4.3. Drugs and Biologicals. Effective 10/01/03. [Website]: <http://www.cms.gov/manuals/Downloads/bp102c15.pdf>. Accessed July 24, 2013.*

*George J. Treatment and prognosis of immune (idiopathic) thrombocytopenia in adults. In: UpToDate Online Journal [serial online]. Waltham, MA: UpToDate; updated April 12, 2013 [Website]: [www.uptodate.com](http://www.uptodate.com). Accessed July 24, 2013.*

*Kuter DJ. New thrombopoietic growth factors. Blood. 2007 Jun 1;109(11):4607-16.*

*Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008 Feb 2;371(9610):395-403.*

POLICY TITLE	THROMBOPOIETIC GROWTH FACTORS
POLICY NUMBER	MP- 2.134

*Kuter D. Clinical applications of thrombopoietic growth factors. In: UpToDate Online Journal [serial online]. Waltham, MA: UpToDate; updated May 30, 2013 [Website]: [www.uptodate.com](http://www.uptodate.com) Accessed July 24, 2013.*

*Kuter D. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. European Journal of Haematology. 80 Supplement 69:9-18, February 2008.*

*Levy, Benjamin; Arnason, Jon E; Bussel, James B The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia. Current Opinion in Oncology. 20(6):690-696, November 2008.*

*MediLexicom drug information Nplate (romiplostim) [Website]: <http://www.medilexicon.com/drugs/nplate.php>. Accessed July 24, 2013.*

*MediLexicom drug information Neumega (oprelvekin) [Website]: <http://www.medilexicon.com/drugs/neumega.php>. Accessed July 24, 2013.*

*National Institute for Health and Clinical Excellence (NICE). Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura [Website]: <http://www.nice.org.uk/nicemedia/live/13467/54219/54219.pdf> Accessed July 23, 2013.*

*Provan, Drew, Stasi, Roberto, Newland Adrian et al. International consensus report on the investigation and management of primary immune thrombocytopenia. [Website]: <http://bloodjournal.hematologylibrary.org/content/115/2/168.full?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=itp&searchid=1&FI>. Accessed July 24, 2013.*

*Risk Evaluation and Mitigation Strategy (REMS) BL 125268 Nplate® (romiplostim) Amgen Inc. [Website]: <http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm129516.pdf>. Accessed July 24, 2013.*

*Romiplostim: Drug information. In: UpToDate Online Journal [serial online]. Waltham, MA: UpToDate; [Website]: [www.uptodate.com](http://www.uptodate.com) Accessed July 23, 2013..*

*Stasi, Roberto 1; Evangelista, Maria L 1; Amadori, Sergio 2 Novel Thrombopoietic Agents: A Review of Their Use in Idiopathic Thrombocytopenic Purpura. Drugs. 68(7):901-912, 2008.*

*Taber's Cyclopedic Medical Dictionary, 20th Edition.*

*Wyeth. Neumega® (oprelvekin) prescribing information. [Website]: [http://www.pfizer.com/files/products/uspi\\_neumega.pdf](http://www.pfizer.com/files/products/uspi_neumega.pdf) . Accessed July 24, 2013.*

**VIII. CODING INFORMATION**

**Note:** This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

### Covered when medically necessary:

HCPCS Code	Description
J2355	INJECTION, OPRELVEKIN, 5 MG
J2796	INJECTION, ROMIPLOSTIM, 10 MICROGRAMS

ICD-9-CM Diagnosis Code*	Description
140.0 – 204.8	MALIGNANT NEOPLASMS
206.0 – 208.9	MALIGNANT NEOPLASMS
230.0 – 238.9	NEOPLASMS
287.31	IMMUNE THROMBOCYTOPENIC PURPURA
287.4	SECONDARY THROMBOCYTOPENIA

\*If applicable, please see Medicare LCD or NCD for additional covered diagnoses.

### The following ICD-10 diagnosis codes will be effective October 1, 2014:

ICD-10-CM Diagnosis Code*	Description
C00.0	Malignant neoplasm of external upper lip
C00.1	Malignant neoplasm of external lower lip
C00.3	Malignant neoplasm of upper lip, inner aspect
C00.4	Malignant neoplasm of lower lip, inner aspect
C00.5	Malignant neoplasm of lip, unspecified, inner aspect
C00.6	Malignant neoplasm of commissure of lip, unspecified
C00.8	Malignant neoplasm of overlapping sites of lip
C00.2	Malignant neoplasm of external lip, unspecified
C00.9	Malignant neoplasm of lip, unspecified
C01	Malignant neoplasm of base of tongue

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C02.0	Malignant neoplasm of dorsal surface of tongue
C02.1	Malignant neoplasm of border of tongue
C02.2	Malignant neoplasm of ventral surface of tongue
C02.3	Malignant neoplasm of anterior two-thirds of tongue, part unspecified
C02.8	Malignant neoplasm of overlapping sites of tongue
C02.4	Malignant neoplasm of lingual tonsil
C02.8	Malignant neoplasm of overlapping sites of tongue
C02.9	Malignant neoplasm of tongue, unspecified
C07	Malignant neoplasm of parotid gland
C08.0	Malignant neoplasm of submandibular gland
C08.1	Malignant neoplasm of sublingual gland
C08.9	Malignant neoplasm of major salivary gland, unspecified
C08.9	Malignant neoplasm of major salivary gland, unspecified
C03.0	Malignant neoplasm of upper gum
C03.1	Malignant neoplasm of lower gum
C03.9	Malignant neoplasm of gum, unspecified
C03.9	Malignant neoplasm of gum, unspecified
C04.0	Malignant neoplasm of anterior floor of mouth
C04.1	Malignant neoplasm of lateral floor of mouth
C04.8	Malignant neoplasm of overlapping sites of floor of mouth
C04.9	Malignant neoplasm of floor of mouth, unspecified
C06.0	Malignant neoplasm of cheek mucosa
C06.1	Malignant neoplasm of vestibule of mouth
C05.0	Malignant neoplasm of hard palate
C05.1	Malignant neoplasm of soft palate
C05.2	Malignant neoplasm of uvula
C05.8	Malignant neoplasm of overlapping sites of palate
C05.9	Malignant neoplasm of palate, unspecified
C06.2	Malignant neoplasm of retromolar area
C06.89	Malignant neoplasm of overlapping sites of other parts of mouth
C06.80	Malignant neoplasm of overlapping sites of unspecified parts of mouth
C06.9	Malignant neoplasm of mouth, unspecified
C09.8	Malignant neoplasm of overlapping sites of tonsil
C09.9	Malignant neoplasm of tonsil, unspecified
C09.0	Malignant neoplasm of tonsillar fossa
C09.1	Malignant neoplasm of tonsillar pillar (anterior) (posterior)
C10.0	Malignant neoplasm of vallecula
C10.1	Malignant neoplasm of anterior surface of epiglottis
C10.8	Malignant neoplasm of overlapping sites of oropharynx
C10.2	Malignant neoplasm of lateral wall of oropharynx

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C10.3	Malignant neoplasm of posterior wall of oropharynx
C10.4	Malignant neoplasm of branchial cleft
C10.8	Malignant neoplasm of overlapping sites of oropharynx
C10.9	Malignant neoplasm of oropharynx, unspecified
C11.0	Malignant neoplasm of superior wall of nasopharynx
C11.1	Malignant neoplasm of posterior wall of nasopharynx
C11.2	Malignant neoplasm of lateral wall of nasopharynx
C11.3	Malignant neoplasm of anterior wall of nasopharynx
C11.8	Malignant neoplasm of overlapping sites of nasopharynx
C11.9	Malignant neoplasm of nasopharynx, unspecified
C13.0	Malignant neoplasm of postcricoid region
C12	Malignant neoplasm of pyriform sinus
C13.1	Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect
C13.2	Malignant neoplasm of posterior wall of hypopharynx
C13.8	Malignant neoplasm of overlapping sites of hypopharynx
C13.9	Malignant neoplasm of hypopharynx, unspecified
C14.0	Malignant neoplasm of pharynx, unspecified
C14.2	Malignant neoplasm of Waldeyer's ring
C14.8	Malignant neoplasm of overlapping sites of lip, oral cavity and pharynx
C14.8	Malignant neoplasm of overlapping sites of lip, oral cavity and pharynx
C15.3	Malignant neoplasm of upper third of esophagus
C15.4	Malignant neoplasm of middle third of esophagus
C15.5	Malignant neoplasm of lower third of esophagus
C15.3	Malignant neoplasm of upper third of esophagus
C15.4	Malignant neoplasm of middle third of esophagus
C15.5	Malignant neoplasm of lower third of esophagus
C15.8	Malignant neoplasm of overlapping sites of esophagus
C15.9	Malignant neoplasm of esophagus, unspecified
C16.0	Malignant neoplasm of cardia
C16.4	Malignant neoplasm of pylorus
C16.3	Malignant neoplasm of pyloric antrum
C16.1	Malignant neoplasm of fundus of stomach
C16.2	Malignant neoplasm of body of stomach
C16.5	Malignant neoplasm of lesser curvature of stomach, unspecified
C16.6	Malignant neoplasm of greater curvature of stomach, unspecified
C16.8	Malignant neoplasm of overlapping sites of stomach
C16.9	Malignant neoplasm of stomach, unspecified
C17.0	Malignant neoplasm of duodenum
C17.1	Malignant neoplasm of jejunum
C17.2	Malignant neoplasm of ileum

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C17.3	Meckel's diverticulum, malignant
C17.8	Malignant neoplasm of overlapping sites of small intestine
C17.9	Malignant neoplasm of small intestine, unspecified
C18.3	Malignant neoplasm of hepatic flexure
C18.4	Malignant neoplasm of transverse colon
C18.6	Malignant neoplasm of descending colon
C18.7	Malignant neoplasm of sigmoid colon
C18.0	Malignant neoplasm of cecum
C18.1	Malignant neoplasm of appendix
C18.2	Malignant neoplasm of ascending colon
C18.5	Malignant neoplasm of splenic flexure
C18.8	Malignant neoplasm of overlapping sites of colon
C18.9	Malignant neoplasm of colon, unspecified
C19	Malignant neoplasm of rectosigmoid junction
C20	Malignant neoplasm of rectum
C21.1	Malignant neoplasm of anal canal
C21.0	Malignant neoplasm of anus, unspecified
C21.2	Malignant neoplasm of cloacogenic zone
C21.8	Malignant neoplasm of overlapping sites of rectum, anus and anal canal
C22.3	Angiosarcoma of liver
C22.2	Hepatoblastoma
C22.0	Liver cell carcinoma
C22.8	Malignant neoplasm of liver, primary, unspecified as to type
C22.4	Other sarcomas of liver
C22.7	Other specified carcinomas of liver
C22.1	Intrahepatic bile duct carcinoma
C22.9	Malignant neoplasm of liver, not specified as primary or secondary
C23	Malignant neoplasm of gallbladder
C24.0	Malignant neoplasm of extrahepatic bile duct
C24.1	Malignant neoplasm of ampulla of Vater
C24.8	Malignant neoplasm of overlapping sites of biliary tract
C24.9	Malignant neoplasm of biliary tract, unspecified
C25.0	Malignant neoplasm of head of pancreas
C25.1	Malignant neoplasm of body of pancreas
C25.2	Malignant neoplasm of tail of pancreas
C25.3	Malignant neoplasm of pancreatic duct
C25.4	Malignant neoplasm of endocrine pancreas
C25.7	Malignant neoplasm of other parts of pancreas
C25.8	Malignant neoplasm of overlapping sites of pancreas
C25.9	Malignant neoplasm of pancreas, unspecified

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C48.0	Malignant neoplasm of retroperitoneum
C48.8	Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum
C48.1	Malignant neoplasm of specified parts of peritoneum
C45.1	Mesothelioma of peritoneum
C48.2	Malignant neoplasm of peritoneum, unspecified
C26.0	Malignant neoplasm of intestinal tract, part unspecified
C26.1	Malignant neoplasm of spleen
C26.9	Malignant neoplasm of ill-defined sites within the digestive system
C26.9	Malignant neoplasm of ill-defined sites within the digestive system
C30.0	Malignant neoplasm of nasal cavity
C30.1	Malignant neoplasm of middle ear
C31.0	Malignant neoplasm of maxillary sinus
C31.1	Malignant neoplasm of ethmoidal sinus
C31.2	Malignant neoplasm of frontal sinus
C31.3	Malignant neoplasm of sphenoid sinus
C31.8	Malignant neoplasm of overlapping sites of accessory sinuses
C31.9	Malignant neoplasm of accessory sinus, unspecified
C32.0	Malignant neoplasm of glottis
C32.1	Malignant neoplasm of supraglottis
C32.2	Malignant neoplasm of subglottis
C32.3	Malignant neoplasm of laryngeal cartilage
C32.8	Malignant neoplasm of overlapping sites of larynx
C32.9	Malignant neoplasm of larynx, unspecified
C33	Malignant neoplasm of trachea
C34.02	Malignant neoplasm of left main bronchus
C34.01	Malignant neoplasm of right main bronchus
C34.00	Malignant neoplasm of unspecified main bronchus
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung
C34.2	Malignant neoplasm of middle lobe, bronchus or lung
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C38.4	Malignant neoplasm of pleura
C45.0	Mesothelioma of pleura
C37	Malignant neoplasm of thymus
C38.0	Malignant neoplasm of heart
C45.2	Mesothelioma
C38.1	Malignant neoplasm of anterior mediastinum
C38.2	Malignant neoplasm of posterior mediastinum
C38.8	Malignant neoplasm of overlapping sites of heart, mediastinum and pleura
C38.3	Malignant neoplasm of mediastinum, part unspecified
C39.0	Malignant neoplasm of upper respiratory tract, part unspecified
C39.9	Malignant neoplasm of lower respiratory tract, part unspecified
C39.9	Malignant neoplasm of lower respiratory tract, part unspecified
C41.0	Malignant neoplasm of bones of skull and face
C41.1	Malignant neoplasm of mandible
C41.2	Malignant neoplasm of vertebral column
C41.3	Malignant neoplasm of ribs, sternum and clavicle
C40.02	Malignant neoplasm of scapula and long bones of left upper limb
C40.01	Malignant neoplasm of scapula and long bones of right upper limb
C40.00	Malignant neoplasm of scapula and long bones of unspecified upper limb
C40.12	Malignant neoplasm of short bones of left upper limb
C40.11	Malignant neoplasm of short bones of right upper limb
C40.10	Malignant neoplasm of short bones of unspecified upper limb
C41.4	Malignant neoplasm of pelvic bones, sacrum and coccyx
C40.22	Malignant neoplasm of long bones of left lower limb
C40.21	Malignant neoplasm of long bones of right lower limb
C40.20	Malignant neoplasm of long bones of unspecified lower limb
C40.32	Malignant neoplasm of short bones of left lower limb
C40.31	Malignant neoplasm of short bones of right lower limb
C40.30	Malignant neoplasm of short bones of unspecified lower limb
C41.9	Malignant neoplasm of bone and articular cartilage, unspecified
C40.82	Malignant neoplasm of overlapping sites of bone and articular cartilage of left limb
C40.81	Malignant neoplasm of overlapping sites of bone and articular cartilage of right limb
C40.80	Malignant neoplasm of overlapping sites of bone and articular cartilage of unspecified limb
C40.92	Malignant neoplasm of unspecified bones and articular cartilage of left limb
C40.91	Malignant neoplasm of unspecified bones and articular cartilage of right limb

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C40.90	Malignant neoplasm of unspecified bones and articular cartilage of unspecified limb
C49.0	Malignant neoplasm of connective and soft tissue of head, face and neck
C47.0	Malignant neoplasm of peripheral nerves of head, face and neck
C49.12	Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder
C49.11	Malignant neoplasm of connective and soft tissue of right upper limb, including shoulder
C49.10	Malignant neoplasm of connective and soft tissue of unspecified upper limb, including shoulder
C47.12	Malignant neoplasm of peripheral nerves of left upper limb, including shoulder
C47.11	Malignant neoplasm of peripheral nerves of right upper limb, including shoulder
C47.10	Malignant neoplasm of peripheral nerves of unspecified upper limb, including shoulder
C49.22	Malignant neoplasm of connective and soft tissue of left lower limb, including hip
C49.21	Malignant neoplasm of connective and soft tissue of right lower limb, including hip
C49.20	Malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip
C47.22	Malignant neoplasm of peripheral nerves of left lower limb, including hip
C47.21	Malignant neoplasm of peripheral nerves of right lower limb, including hip
C47.20	Malignant neoplasm of peripheral nerves of unspecified lower limb, including hip
C49.3	Malignant neoplasm of connective and soft tissue of thorax
C47.3	Malignant neoplasm of peripheral nerves of thorax
C49.4	Malignant neoplasm of connective and soft tissue of abdomen
C47.4	Malignant neoplasm of peripheral nerves of abdomen
C49.5	Malignant neoplasm of connective and soft tissue of pelvis
C47.5	Malignant neoplasm of peripheral nerves of pelvis
C49.6	Malignant neoplasm of connective and soft tissue of trunk, unspecified
C47.6	Malignant neoplasm of peripheral nerves of trunk, unspecified
C49.8	Malignant neoplasm of overlapping sites of connective and soft tissue
C47.8	Malignant neoplasm of overlapping sites of peripheral nerves and autonomic
C49.9	Malignant neoplasm of connective and soft tissue, unspecified
C47.9	Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified
C43.0	Malignant melanoma of lip
D03.0	Melanoma in situ of lip
C43.12	Malignant melanoma of left eyelid, including canthus
C43.11	Malignant melanoma of right eyelid, including canthus
C43.10	Malignant melanoma of unspecified eyelid, including canthus

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

D03.12	Melanoma in situ of left eyelid, including canthus
D03.11	Melanoma in situ of right eyelid, including canthus
D03.10	Melanoma in situ of unspecified eyelid, including canthus
C43.22	Malignant melanoma of left ear and external auricular canal
C43.21	Malignant melanoma of right ear and external auricular canal
C43.20	Malignant melanoma of unspecified ear and external auricular canal
D03.22	Melanoma in situ of left ear and external auricular canal
D03.21	Melanoma in situ of right ear and external auricular canal
D03.20	Melanoma in situ of unspecified ear and external auricular canal
C43.31	Malignant melanoma of nose
C43.39	Malignant melanoma of other parts of face
C43.30	Malignant melanoma of unspecified part of face
D03.39	Melanoma in situ of other parts of face
D03.30	Melanoma in situ of unspecified part of face
C43.4	Malignant melanoma of scalp and neck
D03.4	Melanoma in situ of scalp and neck
C43.51	Malignant melanoma of anal skin
C43.59	Malignant melanoma of other part of trunk
C43.52	Malignant melanoma of skin of breast
D03.51	Melanoma in situ of anal skin
D03.52	Melanoma in situ of breast (skin) (soft tissue)
D03.59	Melanoma in situ of other part of trunk
C43.62	Malignant melanoma of left upper limb, including shoulder
C43.61	Malignant melanoma of right upper limb, including shoulder
C43.60	Malignant melanoma of unspecified upper limb, including shoulder
D03.62	Melanoma in situ of left upper limb, including shoulder
D03.61	Melanoma in situ of right upper limb, including shoulder
D03.60	Melanoma in situ of unspecified upper limb, including shoulder
C43.72	Malignant melanoma of left lower limb, including hip
C43.71	Malignant melanoma of right lower limb, including hip
C43.70	Malignant melanoma of unspecified lower limb, including hip
D03.72	Melanoma in situ of left lower limb, including hip
D03.71	Melanoma in situ of right lower limb, including hip
D03.70	Melanoma in situ of unspecified lower limb, including hip
C43.8	Malignant melanoma of overlapping sites of skin
D03.8	Melanoma in situ of other sites
C43.9	Malignant melanoma of skin, unspecified
D03.9	Melanoma in situ, unspecified
C44.0	Malignant neoplasm of skin of lip
C44.12	Malignant neoplasm of skin of left eyelid, including canthus

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C44.11	Malignant neoplasm of skin of right eyelid, including canthus
C44.10	Malignant neoplasm of skin of unspecified eyelid, including canthus
C44.22	Malignant neoplasm of skin of left ear and external auricular canal
C44.21	Malignant neoplasm of skin of right ear and external auricular canal
C44.20	Malignant neoplasm of skin of unspecified ear and external auricular canal
C44.31	Malignant neoplasm of skin of nose
C44.39	Malignant neoplasm of skin of other parts of face
C44.30	Malignant neoplasm of skin of unspecified part of face
C44.4	Malignant neoplasm of skin of scalp and neck
C44.51	Malignant neoplasm of anal skin
C44.59	Malignant neoplasm of other part of trunk
C44.52	Malignant neoplasm of skin of breast
C44.62	Malignant neoplasm of skin of left upper limb, including shoulder
C44.61	Malignant neoplasm of skin of right upper limb, including shoulder
C44.60	Malignant neoplasm of skin of unspecified upper limb, including shoulder
C44.72	Malignant neoplasm of skin of left lower limb, including hip
C44.71	Malignant neoplasm of skin of right lower limb, including hip
C44.70	Malignant neoplasm of skin of unspecified lower limb, including hip
C44.8	Malignant neoplasm of overlapping sites of skin
C44.9	Malignant neoplasm of skin, unspecified
C50.012	Malignant neoplasm of nipple and areola, left female breast
C50.011	Malignant neoplasm of nipple and areola, right female breast
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast
C50.112	Malignant neoplasm of central portion of
C50.111	Malignant neoplasm of central portion of right female breast
C50.119	Malignant neoplasm of central portion of unspecified female breast
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast
C50.612	Malignant neoplasm of axillary tail of left female breast
C50.611	Malignant neoplasm of axillary tail of right female breast

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C50.619	Malignant neoplasm of axillary tail of unspecified female breast
C50.812	Malignant neoplasm of overlapping sites of left female breast
C50.811	Malignant neoplasm of overlapping sites of right female breast
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast
C50.912	Malignant neoplasm of unspecified site of left female breast
C50.911	Malignant neoplasm of unspecified site of right female breast
C50.919	Malignant neoplasm of unspecified site of unspecified female breast
C50.022	Malignant neoplasm of nipple and areola, left male breast
C50.021	Malignant neoplasm of nipple and areola, right male breast
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast
C50.622	Malignant neoplasm of axillary tail of left male breast
C50.621	Malignant neoplasm of axillary tail of right male breast
C50.629	Malignant neoplasm of axillary tail of unspecified male breast
C50.122	Malignant neoplasm of central portion of left male breast
C50.121	Malignant neoplasm of central portion of right male breast
C50.129	Malignant neoplasm of central portion of unspecified male breast
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast
C50.822	Malignant neoplasm of overlapping sites of left male breast
C50.821	Malignant neoplasm of overlapping sites of right male
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast
C50.922	Malignant neoplasm of unspecified site of left male breast
C50.921	Malignant neoplasm of unspecified site of right male breast
C50.929	Malignant neoplasm of unspecified site of unspecified male breast
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast
C46.0	Kaposi's sarcoma of skin
C46.1	Kaposi's sarcoma of soft tissue
C46.2	Kaposi's sarcoma of palate
C46.4	Kaposi's sarcoma of gastrointestinal sites
C46.52	Kaposi's sarcoma of left lung
C46.51	Kaposi's sarcoma of right lung

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C46.50	Kaposi's sarcoma of unspecified lung
C46.3	Kaposi's sarcoma of lymph nodes
C46.7	Kaposi's sarcoma of other sites
C46.9	Kaposi's sarcoma, unspecified
C55	Malignant neoplasm of uterus, part unspecified
C53.0	Malignant neoplasm of endocervix
C53.1	Malignant neoplasm of exocervix
C53.8	Malignant neoplasm of overlapping sites of cervix uteri
C53.9	Malignant neoplasm of cervix uteri, unspecified
C58	Malignant neoplasm of placenta
C54.9	Malignant neoplasm of corpus uteri, unspecified
C54.1	Malignant neoplasm of endometrium
C54.3	Malignant neoplasm of fundus uteri
C54.2	Malignant neoplasm of myometrium
C54.0	Malignant neoplasm of isthmus uteri
C54.8	Malignant neoplasm of overlapping sites of corpus uteri
C56.2	Malignant neoplasm of left ovary
C56.1	Malignant neoplasm of right ovary
C56.9	Malignant neoplasm of unspecified ovary
C57.02	Malignant neoplasm of left fallopian tube
C57.01	Malignant neoplasm of right fallopian tube
C57.00	Malignant neoplasm of unspecified fallopian tube
C57.12	Malignant neoplasm of left broad ligament
C57.11	Malignant neoplasm of right broad ligament
C57.10	Malignant neoplasm of unspecified broad ligament
C57.3	Malignant neoplasm of parametrium
C57.22	Malignant neoplasm of left round ligament
C57.21	Malignant neoplasm of right round ligament
C57.20	Malignant neoplasm of unspecified round ligament
C57.4	Malignant neoplasm of uterine adnexa, unspecified
C57.4	Malignant neoplasm of uterine adnexa, unspecified
C52	Malignant neoplasm of vagina
C51.0	Malignant neoplasm of labium majus
C51.1	Malignant neoplasm of labium minus
C51.2	Malignant neoplasm of clitoris
C51.9	Malignant neoplasm of vulva, unspecified
C57.7	Malignant neoplasm of other specified female genital organs
C57.8	Malignant neoplasm of overlapping sites of female genital organs
C51.8	Malignant neoplasm of overlapping sites of vulva
C57.9	Malignant neoplasm of female genital organ, unspecified

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C61	Malignant neoplasm of prostate
C62.01	Malignant neoplasm of undescended
C62.02	Malignant neoplasm of undescended left testis
C62.00	Malignant neoplasm of unspecified undescended testis
C62.12	Malignant neoplasm of descended left testis
C62.11	Malignant neoplasm of descended right testis
C62.92	Malignant neoplasm of left testis, unspecified whether descended or undescended
C62.91	Malignant neoplasm of right testis, unspecified whether descended or undescended
C62.10	Malignant neoplasm of unspecified descended testis
C62.90	Malignant neoplasm of unspecified testis, unspecified whether descended or undescended
C60.0	Malignant neoplasm of prepuce
C60.1	Malignant neoplasm of glans penis
C60.2	Malignant neoplasm of body of penis
C60.9	Malignant neoplasm of penis, unspecified
C63.02	Malignant neoplasm of left epididymis
C63.01	Malignant neoplasm of right epididymis
C63.00	Malignant neoplasm of unspecified epididymis
C63.12	Malignant neoplasm of left spermatic cord
C63.11	Malignant neoplasm of right spermatic cord
C63.10	Malignant neoplasm of unspecified spermatic cord
C63.2	Malignant neoplasm of scrotum
C63.7	Malignant neoplasm of other specified male genital organs
C63.8	Malignant neoplasm of overlapping sites of male genital organs
C60.8	Malignant neoplasm of overlapping sites of penis
C63.9	Malignant neoplasm of male genital organ, unspecified
C67.0	Malignant neoplasm of trigone of bladder
C67.1	Malignant neoplasm of dome of bladder
C67.2	Malignant neoplasm of lateral wall of bladder
C67.3	Malignant neoplasm of anterior wall of bladder
C67.4	Malignant neoplasm of posterior wall of bladder
C67.5	Malignant neoplasm of bladder neck
C67.6	Malignant neoplasm of ureteric orifice
C67.7	Malignant neoplasm of urachus
C67.8	Malignant neoplasm of overlapping sites of bladder
C67.9	Malignant neoplasm of bladder, unspecified
C64.2	Malignant neoplasm of left kidney, except renal pelvis
C64.1	Malignant neoplasm of right kidney, except renal pelvis
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis
C65.2	Malignant neoplasm of left renal pelvis

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C65.1	Malignant neoplasm of right renal pelvis
C65.9	Malignant neoplasm of unspecified renal pelvis
C66.2	Malignant neoplasm of left ureter
C66.1	Malignant neoplasm of right ureter
C66.9	Malignant neoplasm of unspecified ureter
C68.0	Malignant neoplasm of urethra
C68.1	Malignant neoplasm of paraurethral glands
C68.8	Malignant neoplasm of overlapping sites of urinary organs
C68.9	Malignant neoplasm of urinary organ, unspecified
C69.42	Malignant neoplasm of left ciliary body
C69.41	Malignant neoplasm of right ciliary body
C69.40	Malignant neoplasm of unspecified ciliary body
C69.62	Malignant neoplasm of left orbit
C69.61	Malignant neoplasm of right orbit
C69.60	Malignant neoplasm of unspecified orbit
C69.52	Malignant neoplasm of left lacrimal gland and duct
C69.51	Malignant neoplasm of right lacrimal gland and duct
C69.50	Malignant neoplasm of unspecified lacrimal gland and duct
C69.02	Malignant neoplasm of left conjunctiva
C69.01	Malignant neoplasm of right conjunctiva
C69.00	Malignant neoplasm of unspecified conjunctiva
C69.12	Malignant neoplasm of left cornea
C69.11	Malignant neoplasm of right cornea
C69.10	Malignant neoplasm of unspecified cornea
C69.22	Malignant neoplasm of left retina
C69.21	Malignant neoplasm of right retina
C69.20	Malignant neoplasm of unspecified retina
C69.32	Malignant neoplasm of left choroid
C69.31	Malignant neoplasm of right choroid
C69.30	Malignant neoplasm of unspecified choroid
C69.52	Malignant neoplasm of left lacrimal gland and duct
C69.51	Malignant neoplasm of right lacrimal gland and duct
C69.50	Malignant neoplasm of unspecified lacrimal gland and duct
C69.82	Malignant neoplasm of overlapping sites of left eye and adnexa
C69.81	Malignant neoplasm of overlapping sites of right eye and adnexa
C69.80	Malignant neoplasm of overlapping sites of unspecified eye and adnexa
C69.92	Malignant neoplasm of unspecified site of left eye
C69.91	Malignant neoplasm of unspecified site of right eye
C69.90	Malignant neoplasm of unspecified site of unspecified eye
C71.0	Malignant neoplasm of cerebrum, except lobes and ventricles

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C71.1	Malignant neoplasm of frontal lobe
C71.2	Malignant neoplasm of temporal lobe
C71.3	Malignant neoplasm of parietal lobe
C71.4	Malignant neoplasm of occipital lobe
C71.5	Malignant neoplasm of cerebral ventricle
C71.6	Malignant neoplasm of cerebellum
C71.7	Malignant neoplasm of brain stem
C71.8	Malignant neoplasm of overlapping sites of brain
C71.9	Malignant neoplasm of brain, unspecified
C72.42	Malignant neoplasm of left acoustic nerve
C72.22	Malignant neoplasm of left olfactory nerve
C72.32	Malignant neoplasm of left optic nerve
C72.59	Malignant neoplasm of other cranial nerves
C72.41	Malignant neoplasm of right acoustic nerve
C72.21	Malignant neoplasm of right olfactory nerve
C72.31	Malignant neoplasm of right optic nerve
C72.40	Malignant neoplasm of unspecified acoustic nerve
C72.50	Malignant neoplasm of unspecified cranial nerve
C72.20	Malignant neoplasm of unspecified olfactory nerve
C72.30	Malignant neoplasm of unspecified optic nerve
C70.0	Malignant neoplasm of cerebral meninges
C70.9	Malignant neoplasm of meninges, unspecified
C72.1	Malignant neoplasm of cauda equina
C72.0	Malignant neoplasm of spinal cord
C70.1	Malignant neoplasm of spinal meninges
C72.9	Malignant neoplasm of central nervous system, unspecified
C72.9	Malignant neoplasm of central nervous system, unspecified
C73	Malignant neoplasm of thyroid gland
C74.02	Malignant neoplasm of cortex of left adrenal gland
C74.01	Malignant neoplasm of cortex of right adrenal gland
C74.00	Malignant neoplasm of cortex of unspecified adrenal gland
C74.12	Malignant neoplasm of medulla of left adrenal gland
C74.11	Malignant neoplasm of medulla of right adrenal gland
C74.10	Malignant neoplasm of medulla of unspecified adrenal gland
C74.92	Malignant neoplasm of unspecified part of left adrenal gland
C74.91	Malignant neoplasm of unspecified part of right adrenal gland
C74.90	Malignant neoplasm of unspecified part of unspecified adrenal gland
C75.0	Malignant neoplasm of parathyroid gland
C75.2	Malignant neoplasm of craniopharyngeal
C75.1	Malignant neoplasm of pituitary gland

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C75.3	Malignant neoplasm of pineal gland
C75.4	Malignant neoplasm of carotid body
C75.5	Malignant neoplasm of aortic body and other paraganglia
C75.8	Malignant neoplasm with pluriglandular involvement, unspecified
C75.9	Malignant neoplasm of endocrine gland, unspecified
C76.0	Malignant neoplasm of head, face and neck
C76.1	Malignant neoplasm of thorax
C76.2	Malignant neoplasm of abdomen
C76.3	Malignant neoplasm of pelvis
C76.42	Malignant neoplasm of left upper limb
C76.41	Malignant neoplasm of right upper limb
C76.40	Malignant neoplasm of unspecified upper limb
C76.52	Malignant neoplasm of left lower limb
C76.51	Malignant neoplasm of right lower limb
C76.50	Malignant neoplasm of unspecified lower limb
C76.8	Malignant neoplasm of other specified ill-defined sites
C45.7	Mesothelioma of other sites
C77.0	Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck
C77.1	Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes
C77.2	Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes
C77.3	Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes
C77.4	Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes
C77.5	Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes
C77.8	Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions
C77.9	Secondary and unspecified malignant neoplasm of lymph node, unspecified
C78.02	Secondary malignant neoplasm of left lung
C78.01	Secondary malignant neoplasm of right lung
C78.00	Secondary malignant neoplasm of unspecified lung
C78.1	Secondary malignant neoplasm of mediastinum
C78.2	Secondary malignant neoplasm of pleura
C78.39	Secondary malignant neoplasm of other respiratory organs
C78.30	Secondary malignant neoplasm of unspecified respiratory organ
C78.4	Secondary malignant neoplasm of small intestine
C78.5	Secondary malignant neoplasm of large intestine and rectum
C78.6	Secondary malignant neoplasm of retroperitoneum and peritoneum
C78.7	Secondary malignant neoplasm of liver and intrahepatic bile duct

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C78.89	Secondary malignant neoplasm of other digestive organs
C78.80	Secondary malignant neoplasm of unspecified digestive organ
C79.02	Secondary malignant neoplasm of left kidney and renal pelvis
C79.01	Secondary malignant neoplasm of right kidney and
C79.00	Secondary malignant neoplasm of unspecified kidney and renal pelvis
C79.11	Secondary malignant neoplasm of bladder
C79.19	Secondary malignant neoplasm of other urinary organs
C79.10	Secondary malignant neoplasm of unspecified urinary organs
C79.2	Secondary malignant neoplasm of skin
C79.31	Secondary malignant neoplasm of brain
C79.32	Secondary malignant neoplasm of cerebral meninges
C79.49	Secondary malignant neoplasm of other parts of
C79.40	Secondary malignant neoplasm of unspecified part of nervous system
C79.51	Secondary malignant neoplasm of bone
C79.52	Secondary malignant neoplasm of bone marrow
C79.62	Secondary malignant neoplasm of left ovary
C79.61	Secondary malignant neoplasm of right ovary
C79.60	Secondary malignant neoplasm of unspecified ovary
C79.72	Secondary malignant neoplasm of left adrenal gland
C79.71	Secondary malignant neoplasm of right adrenal gland
C79.70	Secondary malignant neoplasm of unspecified adrenal gland
C79.81	Secondary malignant neoplasm of breast
C79.82	Secondary malignant neoplasm of genital organs
C79.89	Secondary malignant neoplasm of other specified sites
C79.9	Secondary malignant neoplasm of unspecified site
C80.0	Disseminated malignant neoplasm, unspecified
G73.1	Lambert-Eaton syndrome
C80.1	Malignant (primary) neoplasm, unspecified
C45.9	Mesothelioma, unspecified
C80.2	Malignant neoplasm associated with transplanted organ
C83.39	Diffuse large B-cell lymphoma, extranodal and solid organ sites
C83.30	Diffuse large B-cell lymphoma, unspecified site
C83.31	Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck
C83.32	Diffuse large B-cell lymphoma, intrathoracic lymph nodes
C83.33	Diffuse large B-cell lymphoma, intra-abdominal
C83.34	Diffuse large B-cell lymphoma, lymph nodes of axilla and upper limb
C83.35	Diffuse large B-cell lymphoma, lymph nodes of inguinal region and lower limb
C83.36	Diffuse large B-cell lymphoma, intrapelvic lymph nodes
C83.37	Diffuse large B-cell lymphoma, spleen
C83.38	Diffuse large B-cell lymphoma, lymph nodes of multiple sites

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C83.59	Lymphoblastic (diffuse) lymphoma, extranodal and solid organ sites
C83.50	Lymphoblastic (diffuse) lymphoma, unspecified site
C83.51	Lymphoblastic (diffuse) lymphoma, lymph nodes of head, face, and neck
C83.52	Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes
C83.53	Lymphoblastic (diffuse) lymphoma, intra-abdominal lymph nodes
C83.54	Lymphoblastic (diffuse) lymphoma, lymph nodes of axilla and upper limb
C83.55	Lymphoblastic (diffuse) lymphoma, lymph nodes of inguinal region and lower limb
C83.56	Lymphoblastic (diffuse) lymphoma, intrapelvic lymph nodes
C83.57	Lymphoblastic (diffuse) lymphoma, spleen
C83.58	Lymphoblastic (diffuse) lymphoma, lymph nodes of multiple sites
C83.79	Burkitt lymphoma, extranodal and solid organ sites
C83.70	Burkitt lymphoma, unspecified site
C83.71	Burkitt lymphoma, lymph nodes of head, face, and neck
C83.72	Burkitt lymphoma, intrathoracic lymph nodes
C83.73	Burkitt lymphoma, intra-abdominal lymph nodes
C83.74	Burkitt lymphoma, lymph nodes of axilla and upper limb
C83.75	Burkitt lymphoma, lymph nodes of inguinal region and lower limb
C83.76	Burkitt lymphoma, intrapelvic lymph nodes
C83.77	Burkitt lymphoma, spleen
C83.78	Burkitt lymphoma, lymph nodes of multiple sites
C88.4	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]
C83.89	Other non-follicular lymphoma, extranodal and solid organ sites
C83.80	Other non-follicular lymphoma, unspecified site
C83.81	Other non-follicular lymphoma, lymph nodes of head, face, and neck
C83.82	Other non-follicular lymphoma, intrathoracic lymph nodes
C83.83	Other non-follicular lymphoma, intra-abdominal lymph nodes
C83.84	Other non-follicular lymphoma, lymph nodes of axilla and upper limb
C83.85	Other non-follicular lymphoma, lymph nodes of inguinal region and lower limb
C83.86	Other non-follicular lymphoma, intrapelvic lymph nodes
C83.87	Other non-follicular lymphoma, spleen
C83.88	Other non-follicular lymphoma, lymph nodes of multiple sites
C83.19	Mantle cell lymphoma, extranodal and solid organ sites
C83.10	Mantle cell lymphoma, unspecified site
C83.11	Mantle cell lymphoma, lymph nodes of head, face, and neck
C83.12	Mantle cell lymphoma, intrathoracic lymph nodes
C83.13	Mantle cell lymphoma, intra-abdominal lymph nodes
C83.14	Mantle cell lymphoma, lymph nodes of axilla and upper limb
C83.15	Mantle cell lymphoma, lymph nodes of inguinal region and lower limb

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C83.16	Mantle cell lymphoma, intrapelvic lymph nodes
C83.17	Mantle cell lymphoma, spleen
C83.18	Mantle cell lymphoma, lymph nodes of multiple sites
C83.39	Diffuse large B-cell lymphoma, extranodal and solid organ sites
C83.89	Other non-follicular lymphoma, extranodal and solid organ sites
C83.80	Other non-follicular lymphoma, unspecified site
C83.31	Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck
C83.81	Other non-follicular lymphoma, lymph nodes of head, face, and neck
C83.32	Diffuse large B-cell lymphoma, intrathoracic lymph nodes
C83.82	Other non-follicular lymphoma, intrathoracic lymph nodes
C83.33	Diffuse large B-cell lymphoma, intra-abdominal lymph nodes
C83.83	Other non-follicular lymphoma, intra-abdominal lymph nodes
C83.34	Diffuse large B-cell lymphoma, lymph nodes of axilla and upper limb
C83.84	Other non-follicular lymphoma, lymph nodes of axilla
C83.35	Diffuse large B-cell lymphoma, lymph nodes of inguinal region and lower limb
C83.85	Other non-follicular lymphoma, lymph nodes of inguinal region and lower limb
C83.36	Diffuse large B-cell lymphoma, intrapelvic
C83.86	Other non-follicular lymphoma, intrapelvic lymph nodes
C83.37	Diffuse large B-cell
C83.87	Other non-follicular lymphoma, spleen
C83.38	Diffuse large B-cell lymphoma, lymph nodes of multiple sites
C83.88	Other non-follicular lymphoma, lymph nodes of multiple
C84.79	Anaplastic large cell lymphoma, ALK-negative, extranodal and solid organ sites
C84.70	Anaplastic large cell lymphoma, ALK-negative, unspecified site
C84.69	Anaplastic large cell lymphoma, ALK-positive, extranodal and solid organ sites
C84.60	Anaplastic large cell lymphoma, ALK-positive, unspecified site
C84.71	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of head, face, and neck
C84.61	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of head, face, and neck
C84.72	Anaplastic large cell lymphoma, ALK-negative, intrathoracic
C84.62	Anaplastic large cell lymphoma, ALK-positive, intrathoracic lymph nodes
C84.73	Anaplastic large cell lymphoma, ALK-negative, intra-abdominal lymph nodes
C84.63	Anaplastic large cell lymphoma, ALK-positive, intra-abdominal lymph nodes
C84.74	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of axilla and upper limb
C84.64	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of axilla and upper limb
C84.75	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of inguinal region and lower limb

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C84.65	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of inguinal region and lower limb
C84.76	Anaplastic large cell lymphoma, ALK-negative, intrapelvic lymph nodes
C84.66	Anaplastic large cell lymphoma, ALK-positive, intrapelvic lymph nodes
C84.77	Anaplastic large cell lymphoma, ALK-negative, spleen
C84.67	Anaplastic large cell lymphoma, ALK-positive, spleen
C84.78	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of multiple sites
C84.68	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of multiple sites
C83.39	Diffuse large B-cell lymphoma, extranodal and solid organ sites
C83.31	Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck
C83.32	Diffuse large B-cell lymphoma, intrathoracic lymph nodes
C83.33	Diffuse large B-cell lymphoma, intra-abdominal lymph nodes
C83.34	Diffuse large B-cell lymphoma, lymph nodes of axilla and upper limb
C83.35	Diffuse large B-cell lymphoma, lymph nodes of inguinal region and lower limb
C83.36	Diffuse large B-cell lymphoma, intrapelvic lymph nodes
C83.37	Diffuse large B-cell lymphoma, spleen
C83.38	Diffuse large B-cell lymphoma, lymph nodes of multiple sites
C86.5	Angioimmunoblastic T-cell lymphoma
C83.99	Non-follicular lymphoma, unspecified, extranodal and solid organ sites
C83.90	Non-follicular lymphoma, unspecified, unspecified site
C83.89	Other non-follicular lymphoma, extranodal and solid organ sites
C83.80	Other non-follicular lymphoma, unspecified site
C86.6	Primary cutaneous CD30-positive T-cell proliferations
C83.09	Small cell B-cell lymphoma, extranodal and solid organ sites
C83.00	Small cell B-cell lymphoma, unspecified site
C83.91	Non-follicular lymphoma, unspecified, lymph nodes of head, face, and neck
C83.81	Other non-follicular lymphoma, lymph nodes of head, face, and neck
C83.01	Small cell B-cell lymphoma, lymph nodes of head, face, and neck
C83.92	Non-follicular lymphoma, unspecified, intrathoracic lymph nodes
C83.82	Other non-follicular lymphoma, intrathoracic lymph nodes
C83.02	Small cell B-cell lymphoma, intrathoracic lymph nodes
C83.93	Non-follicular lymphoma, unspecified, intra-abdominal
C83.83	Other non-follicular lymphoma, intra-abdominal lymph nodes
C83.03	Small cell B-cell lymphoma, intra-abdominal lymph nodes
C83.94	Non-follicular lymphoma, unspecified, lymph nodes of axilla and upper limb
C83.84	Other non-follicular lymphoma, lymph nodes of axilla and upper limb
C83.04	Small cell B-cell lymphoma, lymph nodes of axilla and upper limb
C83.95	Non-follicular lymphoma, unspecified, lymph nodes of inguinal region and lower limb
C83.85	Other non-follicular lymphoma, lymph nodes of inguinal region and lower limb

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C83.05	Small cell B-cell lymphoma, lymph nodes of inguinal region and lower limb
C83.96	Non-follicular lymphoma, unspecified, intrapelvic lymph nodes
C83.86	Other non-follicular lymphoma, intrapelvic lymph nodes
C83.06	Small cell B-cell lymphoma, intrapelvic lymph nodes
C83.97	Non-follicular lymphoma, unspecified, spleen
C83.87	Other non-follicular lymphoma, spleen
C83.07	Small cell B-cell lymphoma, spleen
C83.98	Non-follicular lymphoma, unspecified, lymph nodes of multiple sites
C83.88	Other non-follicular lymphoma, lymph nodes of multiple sites
C83.08	Small cell B-cell lymphoma, lymph nodes of multiple sites
C81.79	Other classical Hodgkin lymphoma, extranodal and solid organ sites
C81.70	Other classical Hodgkin lymphoma, unspecified site
C81.71	Other classical Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.72	Other classical Hodgkin lymphoma, intrathoracic lymph nodes
C81.73	Other classical Hodgkin lymphoma, intra-abdominal lymph nodes
C81.74	Other classical Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.75	Other classical Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.77	Other classical Hodgkin lymphoma, spleen
C81.76	Other classical Hodgkin lymphoma, intrapelvic lymph nodes
C81.78	Other classical Hodgkin lymphoma, lymph nodes of multiple sites
C81.79	Other classical Hodgkin lymphoma, extranodal and solid organ sites
C81.70	Other classical Hodgkin lymphoma, unspecified site
C81.71	Other classical Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.72	Other classical Hodgkin lymphoma, intrathoracic lymph nodes
C81.73	Other classical Hodgkin lymphoma, intra-abdominal lymph nodes
C81.74	Other classical Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.75	Other classical Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.76	Other classical Hodgkin lymphoma, intrapelvic lymph nodes
C81.77	Other classical Hodgkin lymphoma, spleen
C81.78	Other classical Hodgkin lymphoma, lymph nodes of multiple sites
C81.79	Other classical Hodgkin lymphoma, extranodal and solid organ sites
C81.70	Other classical Hodgkin lymphoma, unspecified site
C81.71	Other classical Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.72	Other classical Hodgkin lymphoma, intrathoracic lymph nodes
C81.73	Other classical Hodgkin lymphoma, intra-abdominal lymph nodes
C81.74	Other classical Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.75	Other classical Hodgkin lymphoma, lymph nodes of inguinal region and lower limb

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C81.76	Other classical Hodgkin lymphoma, intrapelvic
C81.77	Other classical Hodgkin lymphoma, spleen
C81.78	Other classical Hodgkin lymphoma, lymph nodes of multiple sites
C81.49	Lymphocyte-rich classical Hodgkin lymphoma, extranodal and
C81.40	Lymphocyte-rich classical Hodgkin lymphoma, unspecified site
C81.09	Nodular lymphocyte predominant Hodgkin lymphoma, extranodal and solid organ sites
C81.00	Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site
C81.41	Lymphocyte-rich classical Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.01	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.42	Lymphocyte-rich classical Hodgkin lymphoma, intrathoracic lymph nodes
C81.02	Nodular lymphocyte predominant Hodgkin lymphoma, intrathoracic lymph nodes
C81.43	Lymphocyte-rich classical Hodgkin lymphoma, intra-abdominal lymph nodes
C81.03	Nodular lymphocyte predominant Hodgkin lymphoma, intra-abdominal lymph nodes
C81.44	Lymphocyte-rich classical Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.04	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.45	Lymphocyte-rich classical Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.05	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.46	Lymphocyte-rich classical Hodgkin lymphoma, intrapelvic lymph nodes
C81.06	Nodular lymphocyte predominant Hodgkin lymphoma, intrapelvic lymph nodes
C81.47	Lymphocyte-rich classical Hodgkin lymphoma, spleen
C81.07	Nodular lymphocyte predominant Hodgkin lymphoma, spleen
C81.48	Lymphocyte-rich classical Hodgkin lymphoma, lymph nodes of multiple sites
C81.08	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of multiple sites
C81.19	Nodular sclerosis classical Hodgkin lymphoma, extranodal and solid organ sites
C81.10	Nodular sclerosis classical Hodgkin lymphoma, unspecified site
C81.11	Nodular sclerosis classical Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.12	Nodular sclerosis classical Hodgkin lymphoma, intrathoracic lymph nodes
C81.13	Nodular sclerosis classical Hodgkin lymphoma, intra-abdominal
C81.14	Nodular sclerosis classical Hodgkin lymphoma, lymph nodes of axilla and upper limb

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C81.15	Nodular sclerosis classical Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.16	Nodular sclerosis classical Hodgkin lymphoma, intrapelvic lymph nodes
C81.17	Nodular sclerosis classical Hodgkin lymphoma, spleen
C81.18	Nodular sclerosis classical Hodgkin lymphoma, lymph nodes of multiple sites
C81.29	Mixed cellularity classical Hodgkin lymphoma, extranodal and solid organ sites
C81.20	Mixed cellularity classical Hodgkin lymphoma, unspecified site
C81.21	Mixed cellularity classical Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.22	Mixed cellularity classical Hodgkin lymphoma, intrathoracic lymph nodes
C81.23	Mixed cellularity classical Hodgkin lymphoma, intra-abdominal lymph nodes
C81.24	Mixed cellularity classical Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.25	Mixed cellularity classical Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.26	Mixed cellularity classical Hodgkin lymphoma, intrapelvic lymph nodes
C81.27	Mixed cellularity classical Hodgkin lymphoma, spleen
C81.28	Mixed cellularity classical Hodgkin lymphoma, lymph nodes of multiple sites
C81.39	Lymphocyte depleted classical Hodgkin lymphoma, extranodal and solid organ sites
C81.30	Lymphocyte depleted classical Hodgkin lymphoma, unspecified site
C81.31	Lymphocyte depleted classical Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.32	Lymphocyte depleted classical Hodgkin lymphoma, intrathoracic lymph nodes
C81.33	Lymphocyte depleted classical Hodgkin lymphoma, intra-abdominal lymph nodes
C81.34	Lymphocyte depleted classical Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.35	Lymphocyte depleted classical Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.36	Lymphocyte depleted classical Hodgkin lymphoma, intrapelvic lymph nodes
C81.37	Lymphocyte depleted classical Hodgkin lymphoma, spleen
C81.38	Lymphocyte depleted classical Hodgkin lymphoma, lymph nodes of multiple sites
C81.99	Hodgkin lymphoma, unspecified, extranodal and solid organ sites
C81.90	Hodgkin lymphoma, unspecified, unspecified site
C81.91	Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck
C81.92	Hodgkin lymphoma, unspecified, intrathoracic lymph nodes
C81.93	Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes
C81.94	Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb
C81.95	Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb
C81.96	Hodgkin lymphoma, unspecified, intrapelvic

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C81.97	Hodgkin lymphoma, unspecified, spleen
C81.98	Hodgkin lymphoma, unspecified, lymph nodes of multiple sites
C82.69	Cutaneous follicle center lymphoma, extranodal and solid organ sites
C82.60	Cutaneous follicle center lymphoma, unspecified site
C82.09	Follicular lymphoma grade I, extranodal and solid organ sites
C82.00	Follicular lymphoma grade I, unspecified site
C82.19	Follicular lymphoma grade II, extranodal and solid organ sites
C82.10	Follicular lymphoma grade II, unspecified site
C82.29	Follicular lymphoma grade III, unspecified, extranodal and solid organ sites
C82.20	Follicular lymphoma grade III, unspecified, unspecified site
C82.39	Follicular lymphoma grade IIIa, extranodal and solid organ sites
C82.30	Follicular lymphoma grade IIIa, unspecified site
C82.49	Follicular lymphoma grade IIIb, extranodal and solid organ sites
C82.40	Follicular lymphoma grade IIIb, unspecified site
C82.99	Follicular lymphoma, unspecified, extranodal and solid organ sites
C82.90	Follicular lymphoma, unspecified, unspecified site
C82.89	Other types of follicular lymphoma, extranodal and solid organ sites
C82.80	Other types of follicular lymphoma, unspecified site
C82.61	Cutaneous follicle center lymphoma, lymph nodes of head
C82.01	Follicular lymphoma grade I, lymph nodes of head, face, and neck
C82.11	Follicular lymphoma grade II, lymph nodes of head, face, and neck
C82.21	Follicular lymphoma grade III, unspecified, lymph nodes of head, face, and neck
C82.31	Follicular lymphoma grade IIIa, lymph nodes of head, face, and neck
C82.41	Follicular lymphoma grade IIIb, lymph nodes of head, face, and neck
C82.91	Follicular lymphoma, unspecified, lymph nodes of head, face, and neck
C82.81	Other types of follicular lymphoma, lymph nodes of head, face, and neck
C82.62	Cutaneous follicle center lymphoma, intrathoracic lymph nodes
C82.02	Follicular lymphoma grade I, intrathoracic lymph nodes
C82.12	Follicular lymphoma grade II, intrathoracic lymph nodes
C82.22	Follicular lymphoma grade III, unspecified, intrathoracic lymph nodes
C82.32	Follicular lymphoma grade IIIa, intrathoracic lymph nodes
C82.42	Follicular lymphoma grade IIIb, intrathoracic lymph nodes
C82.92	Follicular lymphoma, unspecified, intrathoracic
C82.82	Other types of follicular lymphoma, intrathoracic lymph nodes
C82.63	Cutaneous follicle center lymphoma, intra-abdominal lymph nodes
C82.03	Follicular lymphoma grade I, intra-abdominal lymph nodes
C82.13	Follicular lymphoma grade II, intra-abdominal lymph nodes
C82.23	Follicular lymphoma grade III, unspecified, intra-abdominal lymph nodes
C82.33	Follicular lymphoma grade IIIa, intra-abdominal lymph nodes
C82.43	Follicular lymphoma grade IIIb, intra-abdominal

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C82.93	Follicular lymphoma, unspecified, intra-abdominal lymph nodes
C82.83	Other types of follicular lymphoma, intra-abdominal
C82.64	Cutaneous follicle center lymphoma, lymph nodes of axilla and upper limb
C82.04	Follicular lymphoma grade I, lymph nodes of axilla and upper limb
C82.14	Follicular lymphoma grade II, lymph nodes of axilla and upper limb
C82.24	Follicular lymphoma grade III, unspecified, lymph nodes of axilla and upper limb
C82.34	Follicular lymphoma grade IIIa, lymph nodes of axilla and upper limb
C82.44	Follicular lymphoma grade IIIb, lymph nodes of axilla and upper limb
C82.94	Follicular lymphoma, unspecified, lymph nodes of axilla and upper limb
C82.84	Other types of follicular lymphoma, lymph nodes of axilla and upper limb
C82.65	Cutaneous follicle center lymphoma, lymph nodes of inguinal region and lower limb
C82.05	Follicular lymphoma grade I, lymph nodes of inguinal region and lower limb
C82.15	Follicular lymphoma grade II, lymph nodes of inguinal region and lower limb
C82.25	Follicular lymphoma grade III, unspecified, lymph nodes of inguinal region and lower limb
C82.35	Follicular lymphoma grade IIIa, lymph nodes of inguinal region and lower limb
C82.45	Follicular lymphoma grade IIIb, lymph nodes of inguinal region and lower limb
C82.95	Follicular lymphoma, unspecified, lymph nodes of inguinal region and lower limb
C82.85	Other types of follicular lymphoma, lymph nodes of inguinal region and lower limb
C82.66	Cutaneous follicle center lymphoma, intrapelvic lymph nodes
C82.06	Follicular lymphoma grade I, intrapelvic lymph nodes
C82.16	Follicular lymphoma grade II, intrapelvic lymph nodes
C82.26	Follicular lymphoma grade III, unspecified, intrapelvic lymph nodes
C82.36	Follicular lymphoma grade IIIa, intrapelvic
C82.46	Follicular lymphoma grade IIIb, intrapelvic lymph nodes
C82.96	Follicular lymphoma, unspecified, intrapelvic
C82.86	Other types of follicular lymphoma, intrapelvic lymph nodes
C82.67	Cutaneous follicle center lymphoma, spleen
C82.07	Follicular lymphoma grade I, spleen
C82.17	Follicular lymphoma grade II, spleen
C82.27	Follicular lymphoma grade III, unspecified, spleen
C82.37	Follicular lymphoma grade IIIa, spleen
C82.47	Follicular lymphoma grade IIIb, spleen
C82.97	Follicular lymphoma, unspecified, spleen
C82.87	Other types of follicular lymphoma, spleen
C82.68	Cutaneous follicle center lymphoma, lymph nodes of multiple sites
C82.08	Follicular lymphoma grade I, lymph nodes of multiple sites
C82.18	Follicular lymphoma grade II, lymph nodes of multiple sites

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C82.28	Follicular lymphoma grade III, unspecified, lymph nodes of multiple sites
C82.38	Follicular lymphoma grade IIIa, lymph nodes of multiple sites
C82.48	Follicular lymphoma grade IIIb, lymph nodes of multiple sites
C82.98	Follicular lymphoma, unspecified, lymph nodes of multiple sites
C82.88	Other types of follicular lymphoma, lymph nodes of multiple sites
C84.09	Mycosis fungoides, extranodal and solid organ sites
C84.00	Mycosis fungoides, unspecified site
C84.01	Mycosis fungoides, lymph nodes of head, face, and neck
C84.02	Mycosis fungoides, intrathoracic lymph nodes
C84.03	Mycosis fungoides, intra-abdominal lymph nodes
C84.04	Mycosis fungoides, lymph nodes of axilla and upper limb
C84.05	Mycosis fungoides, lymph nodes of inguinal region and lower limb
C84.06	Mycosis fungoides, intrapelvic lymph nodes
C84.07	Mycosis fungoides, spleen
C84.08	Mycosis fungoides, lymph nodes of multiple sites
C84.19	Sezary disease, extranodal and solid organ sites
C84.10	Sezary disease, unspecified site
C84.11	Sezary disease, lymph nodes of head, face, and neck
C84.12	Sezary disease, intrathoracic lymph nodes
C84.13	Sezary disease, intra-abdominal lymph nodes
C84.14	Sezary disease, lymph nodes of axilla and upper limb
C84.15	Sezary disease, lymph nodes of inguinal region and lower limb
C84.16	Sezary disease, intrapelvic lymph nodes
C84.17	Sezary disease, spleen
C84.18	Sezary disease, lymph nodes of multiple sites
C96.a	Histiocytic sarcoma
C91.40	Hairy cell leukemia not having achieved remission
C91.42	Hairy cell leukemia, in relapse
C91.41	Hairy cell leukemia, in remission
C91.40	Hairy cell leukemia not having achieved remission
C91.40	Hairy cell leukemia not having achieved remission
C91.40	Hairy cell leukemia not having achieved remission

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C91.40	Hairy cell leukemia not having achieved remission
C91.40	Hairy cell leukemia not having achieved remission
C91.40	Hairy cell leukemia not having achieved remission
C91.40	Hairy cell leukemia not having achieved remission
C91.40	Hairy cell leukemia not having achieved remission
C96.0	Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis
C96.0	Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis
C96.0	Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis
C96.0	Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis
C96.0	Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis
C96.0	Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis
C96.0	Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis
C96.0	Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis
C96.0	Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis
C96.2	Malignant mast cell tumor
C96.2	Malignant
C96.2	Malignant mast cell tumor
C85.29	Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites
C85.20	Mediastinal (thymic) large B-cell lymphoma, unspecified site
C84.49	Peripheral T-cell lymphoma, not classified, extranodal and solid organ sites
C84.40	Peripheral T-cell lymphoma, not classified, unspecified site
C85.21	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face, and neck
C84.41	Peripheral T-cell lymphoma, not classified, lymph nodes of head, face, and neck
C85.22	Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes
C84.42	Peripheral T-cell lymphoma, not classified, intrathoracic lymph nodes
C85.23	Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes
C84.43	Peripheral T-cell lymphoma, not classified, intra-abdominal lymph nodes
C85.24	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb
C84.44	Peripheral T-cell lymphoma, not classified, lymph nodes of axilla and upper limb
C85.25	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb
C84.45	Peripheral T-cell lymphoma, not classified, lymph nodes of inguinal region and lower limb

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C85.26	Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes
C84.46	Peripheral T-cell lymphoma, not classified, intrapelvic lymph nodes
C85.27	Mediastinal (thymic) large B-cell lymphoma, spleen
C84.47	Peripheral T-cell lymphoma, not classified, spleen
C85.28	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites
C84.48	Peripheral T-cell lymphoma, not classified, lymph nodes of multiple sites
C86.4	Blastic NK-cell lymphoma
C84.a9	Cutaneous T-cell lymphoma, unspecified, extranodal and solid organ sites
C84.a0	Cutaneous T-cell lymphoma, unspecified, unspecified site
C82.59	Diffuse follicle center lymphoma, extranodal and solid organ sites
C82.50	Diffuse follicle center lymphoma, unspecified site
C84.99	Mature T/NK-cell lymphomas, unspecified, extranodal and solid organ sites
C84.90	Mature T/NK-cell lymphomas, unspecified, unspecified site
C85.29	Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites
C85.20	Mediastinal (thymic) large B-cell lymphoma, unspecified site
C85.99	Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites
C85.90	Non-Hodgkin lymphoma, unspecified, unspecified site
C84.z9	Other mature T/NK-cell lymphomas, extranodal and solid organ sites
C84.z0	Other mature T/NK-cell lymphomas, unspecified site
C85.89	Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites
C85.80	Other specified types of non-Hodgkin lymphoma, unspecified site
C85.19	Unspecified B-cell lymphoma, extranodal and solid organ sites
C85.10	Unspecified B-cell lymphoma, unspecified site
C84.a1	Cutaneous T-cell lymphoma, unspecified lymph nodes of head, face, and neck
C82.51	Diffuse follicle center lymphoma, lymph nodes of head, face, and neck
C86.0	Extranodal NK/T-cell lymphoma, nasal type
C84.91	Mature T/NK-cell lymphomas, unspecified, lymph nodes of head, face, and neck
C85.21	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face, and neck
C85.91	Non-Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck
C84.z1	Other mature T/NK-cell lymphomas, lymph nodes of head, face, and neck
C85.81	Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face, and neck
C85.11	Unspecified B-cell lymphoma, lymph nodes of head, face, and neck
C84.a2	Cutaneous T-cell lymphoma, unspecified, intrathoracic lymph nodes
C82.52	Diffuse follicle center lymphoma, intrathoracic lymph nodes
C84.92	Mature T/NK-cell lymphomas, unspecified, intrathoracic lymph nodes
C85.22	Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes
C85.92	Non-Hodgkin lymphoma, unspecified, intrathoracic lymph nodes
C84.z2	Other mature T/NK-cell lymphomas, intrathoracic lymph nodes
C85.82	Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C85.12	Unspecified B-cell lymphoma, intrathoracic lymph nodes
C84.a3	Cutaneous T-cell lymphoma, unspecified, intra-abdominal lymph nodes
C82.53	Diffuse follicle center lymphoma, intra-abdominal lymph nodes
C86.2	Enteropathy-type (intestinal) T-cell lymphoma
C84.93	Mature T/NK-cell lymphomas, unspecified, intra-abdominal lymph nodes
C85.23	Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes
C85.93	Non-Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes
C84.z3	Other mature T/NK-cell lymphomas, intra-abdominal lymph nodes
C85.83	Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph nodes
C86.3	Subcutaneous panniculitis-like T-cell lymphoma
C85.13	Unspecified B-cell lymphoma, intra-abdominal lymph nodes
C84.a4	Cutaneous T-cell lymphoma, unspecified, lymph nodes of axilla and upper limb
C82.54	Diffuse follicle center lymphoma, lymph nodes of axilla and upper limb
C84.94	Mature T/NK-cell lymphomas, unspecified, lymph nodes of axilla and upper limb
C85.24	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb
C85.94	Non-Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb
C84.z4	Other mature T/NK-cell lymphomas, lymph nodes of axilla and upper limb
C85.84	Other specified types of non-Hodgkin lymphoma, lymph nodes of axilla and upper limb
C85.14	Unspecified B-cell lymphoma, lymph nodes of axilla and upper limb
C84.a5	Cutaneous T-cell lymphoma, unspecified, lymph nodes of inguinal region and lower limb
C82.55	Diffuse follicle center lymphoma, lymph nodes of inguinal region and lower limb
C84.95	Mature T/NK-cell lymphomas, unspecified, lymph nodes of inguinal region and lower limb
C85.25	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb
C85.95	Non-Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb
C84.z5	Other mature T/NK-cell lymphomas, lymph nodes of inguinal region and lower limb
C85.85	Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C85.15	Unspecified B-cell lymphoma, lymph nodes of inguinal region and lower limb
C84.a6	Cutaneous T-cell lymphoma, unspecified, intrapelvic lymph nodes
C82.56	Diffuse follicle center lymphoma, intrapelvic lymph nodes
C84.96	Mature T/NK-cell lymphomas, unspecified, intrapelvic lymph nodes
C85.26	Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes
C85.96	Non-Hodgkin lymphoma, unspecified, intrapelvic lymph nodes
C84.z6	Other mature T/NK-cell lymphomas, intrapelvic lymph nodes

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C85.86	Other specified types of non-Hodgkin lymphoma, intrapelvic lymph nodes
C85.16	Unspecified B-cell lymphoma, intrapelvic lymph nodes
C84.a7	Cutaneous T-cell lymphoma, unspecified, spleen
C82.57	Diffuse follicle center lymphoma, spleen
C86.1	Hepatosplenic T-cell lymphoma
C84.97	Mature T/NK-cell lymphomas, unspecified, spleen
C85.27	Mediastinal (thymic) large B-cell lymphoma, spleen
C85.97	Non-Hodgkin lymphoma, unspecified, spleen
C84.z7	Other mature T/NK-cell lymphomas, spleen
C85.87	Other specified types of non-Hodgkin lymphoma, spleen
C85.17	Unspecified B-cell lymphoma, spleen
C84.a8	Cutaneous T-cell lymphoma, unspecified, lymph nodes of multiple sites
C82.58	Diffuse follicle center lymphoma, lymph nodes of multiple sites
C84.98	Mature T/NK-cell lymphomas, unspecified, lymph nodes of multiple sites
C85.28	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites
C85.98	Non-Hodgkin lymphoma, unspecified, lymph nodes of multiple sites
C84.z8	Other mature T/NK-cell lymphomas, lymph nodes of multiple sites
C85.88	Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple sites
C85.18	Unspecified B-cell lymphoma, lymph nodes of multiple sites
C96.9	Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified
C96.z	Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue
C96.4	Sarcoma of dendritic cells (accessory cells)
C96.9	Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified
C96.z	Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue
C96.9	Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified
C96.z	Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue
C96.9	Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified
C96.z	Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue
C96.9	Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified
C96.z	Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue
C96.9	Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified
C96.z	Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue
C96.9	Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified
C96.z	Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

	tissue
C96.9	Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified
C96.z	Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue
C96.9	Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified
C96.z	Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue
C90.00	Multiple myeloma not having achieved remission
C90.01	Multiple myeloma in remission
C90.02	Multiple myeloma in relapse
C90.10	Plasma cell leukemia not having achieved remission
C90.11	Plasma cell leukemia in remission
C90.12	Plasma cell leukemia in relapse
C90.20	Extramedullary plasmacytoma not having achieved remission
C88.2	Heavy chain disease
C88.3	Immunoproliferative small intestinal disease
C88.9	Malignant immunoproliferative disease, unspecified
C88.8	Other malignant immunoproliferative diseases
C90.30	Solitary plasmacytoma not having achieved remission
C90.21	Extramedullary plasmacytoma in remission
C88.2	Heavy chain
C88.8	Other malignant immunoproliferative diseases
C90.31	Solitary plasmacytoma in remission
C90.22	Extramedullary plasmacytoma in relapse
C88.8	Other malignant immunoproliferative diseases
C90.32	Solitary plasmacytoma in relapse
C91.00	Acute lymphoblastic leukemia not having achieved remission
C91.01	Acute lymphoblastic leukemia, in remission
C91.02	Acute lymphoblastic leukemia, in relapse
C91.10	Chronic lymphocytic leukemia of B-cell type not having achieved remission
C91.11	Chronic lymphocytic leukemia of B-cell type in remission
C91.12	Chronic lymphocytic leukemia of B-cell type in relapse
C91.z0	Other lymphoid leukemia not having achieved remission
C91.z1	Other lymphoid leukemia, in remission
C91.z2	Other lymphoid leukemia, in relapse
C91.50	Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having achieved remission
C91.a0	Mature B-cell leukemia Burkitt-type not having achieved remission
C91.z0	Other lymphoid leukemia not having achieved remission
C91.30	Prolymphocytic leukemia of B-cell type not having achieved remission

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C91.60	Prolymphocytic leukemia of T-cell type not having achieved remission
C91.51	Adult T-cell lymphoma/leukemia (HTLV-1-associated), in remission
C91.a1	Mature B-cell leukemia Burkitt-type, in remission
C91.z1	Other lymphoid leukemia, in remission
C91.31	Prolymphocytic leukemia of B-cell type, in remission
C91.61	Prolymphocytic leukemia of T-cell type, in remission
C91.52	Adult T-cell lymphoma/leukemia (HTLV-1-associated), in relapse
C91.a2	Mature B-cell leukemia Burkitt-type, in relapse
C91.z2	Other lymphoid leukemia, in relapse
C91.32	Prolymphocytic leukemia of B-cell type, in relapse
C91.62	Prolymphocytic leukemia of T-cell type, in relapse
C93.00	Acute monoblastic/monocytic leukemia, not having achieved remission
C93.01	Acute monoblastic/monocytic leukemia, in remission
C93.02	Acute monoblastic/monocytic leukemia, in relapse
C93.10	Chronic myelomonocytic leukemia not having achieved remission
C93.11	Chronic myelomonocytic leukemia, in remission
C93.12	Chronic myelomonocytic leukemia, in relapse
C93.90	Monocytic leukemia, unspecified, not having achieved remission
C93.91	Monocytic leukemia, unspecified in remission
C93.92	Monocytic leukemia, unspecified in relapse
C93.30	Juvenile myelomonocytic leukemia, not having achieved remission
C93.z0	Other monocytic leukemia, not in remission
C93.31	Juvenile myelomonocytic leukemia, in remission
C93.z1	Other monocytic leukemia, in remission
C93.32	Juvenile myelomonocytic leukemia, in relapse
C93.z0	Other monocytic leukemia, not in remission
C93.90	Monocytic leukemia, unspecified, not having achieved remission
C93.91	Monocytic leukemia, unspecified in remission
C93.92	Monocytic leukemia, unspecified in relapse
C94.00	Acute erythroid leukemia, not having achieved remission
C94.01	Acute erythroid leukemia, in remission
C94.02	Acute erythroid leukemia, in relapse
D45	Polycythemia vera
D45	Polycythemia vera
D45	Polycythemia vera
C94.20	Acute megakaryoblastic leukemia not having achieved remission
C94.21	Acute megakaryoblastic leukemia, in remission
C94.22	Acute megakaryoblastic leukemia, in relapse
C94.30	Mast cell leukemia not having achieved remission
C94.80	Other specified leukemias not having achieved remission

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

C94.31	Mast cell leukemia, in remission
C94.81	Other specified leukemias, in remission
C94.32	Mast cell leukemia, in relapse
C94.82	Other specified leukemias, in relapse
C95.00	Acute leukemia of unspecified cell type not having achieved remission
C95.01	Acute leukemia of unspecified cell type, in remission
C95.02	Acute leukemia of unspecified cell type, in relapse
C95.10	Chronic leukemia of unspecified cell type not having achieved remission
C95.11	Chronic leukemia of unspecified cell type, in remission
C95.12	Chronic leukemia of unspecified cell type, in relapse
C95.90	Leukemia, unspecified not having achieved remission
C95.91	Leukemia, unspecified, in remission
C95.92	Leukemia, unspecified, in relapse
C95.90	Leukemia, unspecified not having achieved remission
C95.91	Leukemia, unspecified, in remission
C95.92	Leukemia, unspecified, in relapse
C95.90	Leukemia, unspecified not having achieved remission
C95.91	Leukemia, unspecified, in remission
C95.92	Leukemia, unspecified, in relapse
D00.02	Carcinoma in situ of buccal mucosa
D00.06	Carcinoma in situ of floor of mouth
D00.03	Carcinoma in situ of gingiva and edentulous alveolar ridge
D00.05	Carcinoma in situ of hard palate
D00.01	Carcinoma in situ of labial mucosa and vermilion border
D00.00	Carcinoma in situ of oral cavity, unspecified site
D00.08	Carcinoma in situ of pharynx
D00.04	Carcinoma in situ of soft palate
D00.07	Carcinoma in situ of tongue
D00.1	Carcinoma in situ of esophagus
D00.2	Carcinoma in situ of stomach
D01.0	Carcinoma in situ of colon
D01.1	Carcinoma in situ of rectosigmoid junction
D01.2	Carcinoma in situ of rectum
D01.3	Carcinoma in situ of anus and anal canal
D01.3	Carcinoma in situ of anus and anal canal
D01.49	Carcinoma in situ of other parts of intestine
D01.40	Carcinoma in situ of unspecified part of intestine
D01.5	Carcinoma in situ of liver, gallbladder and bile ducts
D01.9	Carcinoma in situ of digestive organ, unspecified
D01.7	Carcinoma in situ of other specified digestive organs

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

D02.0	Carcinoma in situ of larynx
D02.1	Carcinoma in situ of trachea
D02.22	Carcinoma in situ of left bronchus and lung
D02.21	Carcinoma in situ of right bronchus and lung
D02.20	Carcinoma in situ of unspecified bronchus and lung
D02.3	Carcinoma in situ of other parts of respiratory system
D02.4	Carcinoma in situ of respiratory system, unspecified
D04.0	Carcinoma in situ of skin of lip
D04.12	Carcinoma in situ of skin of left eyelid, including canthus
D04.11	Carcinoma in situ of skin of right eyelid, including canthus
D04.10	Carcinoma in situ of skin of unspecified eyelid, including canthus
D04.22	Carcinoma in situ of skin of left ear and external auricular canal
D04.21	Carcinoma in situ of skin of right ear and external auricular canal
D04.20	Carcinoma in situ of skin of unspecified ear and external auricular canal
D04.39	Carcinoma in situ of skin of other parts of face
D04.30	Carcinoma in situ of skin of unspecified part of face
D04.4	Carcinoma in situ of skin of scalp and neck
D04.5	Carcinoma in situ of skin of trunk
D04.62	Carcinoma in situ of skin of left upper limb, including shoulder
D04.61	Carcinoma in situ of skin of right upper limb, including shoulder
D04.60	Carcinoma in situ of skin of unspecified upper limb, including shoulder
D04.72	Carcinoma in situ of skin of left lower limb, including hip
D04.71	Carcinoma in situ of skin of right lower limb, including hip
D04.70	Carcinoma in situ of skin of unspecified lower limb, including hip
D04.8	Carcinoma in situ of skin of other sites
D04.9	Carcinoma in situ of skin, unspecified
D05.11	Intraductal carcinoma in
D05.12	Intraductal carcinoma in situ of left breast
D05.10	Intraductal carcinoma in situ of unspecified breast
D05.02	Lobular carcinoma in situ of left breast
D05.01	Lobular carcinoma in situ of right breast
D05.00	Lobular carcinoma in situ of unspecified breast
D05.82	Other specified type of carcinoma in situ of left breast
D05.81	Other specified type of carcinoma in situ of right breast
D05.80	Other specified type of carcinoma in situ of unspecified breast
D05.92	Unspecified type of carcinoma in situ of left breast
D05.91	Unspecified type of carcinoma in situ of right breast
D05.90	Unspecified type of carcinoma in situ of unspecified breast
D06.9	Carcinoma in situ of cervix, unspecified

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

D06.0	Carcinoma in situ of endocervix
D06.1	Carcinoma in situ of exocervix
D06.7	Carcinoma in situ of other parts of cervix
D07.0	Carcinoma in situ of endometrium
D07.30	Carcinoma in situ of unspecified female genital organs
D07.2	Carcinoma in situ of vagina
D07.1	Carcinoma in situ of vulva
D07.39	Carcinoma in situ of other female genital organs
D07.5	Carcinoma in situ of prostate
D07.4	Carcinoma in situ of penis
D07.69	Carcinoma in situ of other male genital organs
D07.61	Carcinoma in situ of scrotum
D07.60	Carcinoma in situ of unspecified male genital organs
D09.0	Carcinoma in situ of bladder
D09.19	Carcinoma in situ of other urinary organs
D09.10	Carcinoma in situ of unspecified urinary organ
D09.22	Carcinoma in situ of left eye
D09.21	Carcinoma in situ of right eye
D09.20	Carcinoma in situ of unspecified eye
D09.8	Carcinoma in situ of other specified sites
D09.3	Carcinoma in situ of thyroid and other endocrine glands
D09.9	Carcinoma in situ, unspecified
D37.039	Neoplasm of uncertain behavior of the major salivary glands, unspecified
D37.030	Neoplasm of uncertain behavior of the parotid salivary glands
D37.031	Neoplasm of uncertain behavior of the sublingual salivary glands
D37.032	Neoplasm of uncertain behavior of the submandibular salivary glands
D37.01	Neoplasm of uncertain behavior of lip
D37.09	Neoplasm of uncertain behavior of other specified sites of the oral cavity
D37.05	Neoplasm of uncertain behavior of pharynx
D37.04	Neoplasm of uncertain behavior of the minor salivary glands
D37.02	Neoplasm of uncertain behavior of tongue
D37.3	Neoplasm of uncertain behavior of appendix
D37.4	Neoplasm of uncertain behavior of colon
D37.5	Neoplasm of uncertain behavior of rectum
D37.2	Neoplasm of uncertain behavior of small intestine
D37.1	Neoplasm of uncertain behavior of stomach
D37.6	Neoplasm of uncertain behavior of liver, gallbladder and bile ducts
D48.4	Neoplasm of uncertain behavior of peritoneum
D48.3	Neoplasm of uncertain behavior of retroperitoneum
D37.9	Neoplasm of uncertain behavior of digestive organ, unspecified

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

D37.8	Neoplasm of uncertain behavior of other specified digestive organs
D38.0	Neoplasm of uncertain behavior of larynx
D38.1	Neoplasm of uncertain behavior of trachea, bronchus and lung
D38.3	Neoplasm of uncertain behavior of mediastinum
D38.2	Neoplasm of uncertain behavior of pleura
D38.4	Neoplasm of uncertain behavior of thymus
D38.5	Neoplasm of uncertain behavior of other respiratory organs
D38.6	Neoplasm of uncertain behavior of respiratory organ, unspecified
D39.0	Neoplasm of uncertain behavior of uterus
D39.2	Neoplasm of uncertain behavior of placenta
D39.12	Neoplasm of uncertain behavior of left ovary
D39.11	Neoplasm of uncertain behavior of right ovary
D39.10	Neoplasm of uncertain behavior of unspecified ovary
D39.9	Neoplasm of uncertain behavior of female genital
D39.8	Neoplasm of uncertain behavior of other specified female genital organs
D40.12	Neoplasm of uncertain behavior of left testis
D40.11	Neoplasm of uncertain behavior of right testis
D40.10	Neoplasm of uncertain behavior of unspecified testis
D40.0	Neoplasm of uncertain behavior of prostate
D40.9	Neoplasm of uncertain behavior of male genital organ, unspecified
D40.8	Neoplasm of uncertain behavior of other specified male genital organs
D41.4	Neoplasm of uncertain behavior of bladder
D41.9	Neoplasm of uncertain behavior of unspecified urinary organ
D41.12	Neoplasm of uncertain behavior
D41.21	Neoplasm of uncertain behavior
D41.02	Neoplasm of uncertain behavior of left kidney
D41.22	Neoplasm of uncertain behavior of left ureter
D41.01	Neoplasm of uncertain behavior of right kidney
D41.11	Neoplasm of uncertain behavior of right renal pelvis
D41.00	Neoplasm of uncertain behavior of unspecified kidney
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis
D41.20	Neoplasm of uncertain behavior of unspecified ureter
D41.8	Neoplasm of uncertain behavior of other specified urinary organs
D41.3	Neoplasm of uncertain behavior of urethra
D44.4	Neoplasm of uncertain behavior of craniopharyngeal duct
D44.3	Neoplasm of uncertain behavior of pituitary gland
D44.5	Neoplasm of uncertain behavior of pineal gland
D44.12	Neoplasm of uncertain behavior
D44.11	Neoplasm of uncertain behavior of right adrenal gland
D44.10	Neoplasm of uncertain behavior of unspecified adrenal gland

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

D44.7	Neoplasm of uncertain behavior of aortic body and other paraganglia
D44.6	Neoplasm of uncertain behavior of carotid body
D44.2	Neoplasm of uncertain behavior of parathyroid gland
D44.0	Neoplasm of uncertain behavior of thyroid gland
D44.9	Neoplasm of uncertain behavior of unspecified endocrine gland
D43.0	Neoplasm of uncertain behavior of brain,
D43.1	Neoplasm of uncertain behavior of brain, infratentorial
D43.2	Neoplasm of uncertain behavior of brain, unspecified
D43.4	Neoplasm of uncertain behavior of spinal cord
D42.0	Neoplasm of uncertain behavior of cerebral meninges
D42.9	Neoplasm of uncertain behavior of meninges
D42.1	Neoplasm of uncertain behavior of spinal meninges
Q85.00	Neurofibromatosis, unspecified
Q85.01	Neurofibromatosis, type 1
Q85.02	Neurofibromatosis, type 2
Q85.03	Schwannomatosis
Q85.09	Other neurofibromatosis
D43.3	Neoplasm of uncertain behavior
D43.9	Neoplasm of uncertain behavior of central nervous system, unspecified
D43.8	Neoplasm of uncertain behavior of other specified parts of central nervous system
D48.0	Neoplasm of uncertain behavior of bone and articular cartilage
D48.1	Neoplasm of uncertain behavior of connective and other soft tissue
D48.2	Neoplasm of uncertain behavior of peripheral nerves and autonomic nervous system
D48.5	Neoplasm of uncertain behavior of skin
D48.62	Neoplasm of uncertain behavior of left breast
D48.61	Neoplasm of uncertain behavior of right breast
D48.60	Neoplasm of uncertain behavior of unspecified breast
D45	Polycythemia vera
D47.0	Histiocytic and mast cell tumors of uncertain behavior
D47.z9	Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue
D47.3	Essential (hemorrhagic) thrombocythemia
D46.9	Myelodysplastic syndrome, unspecified
D46.21	Refractory anemia with excess of blasts 1
D46.20	Refractory anemia with excess of blasts, unspecified
D46.1	Refractory anemia with ring sideroblasts
D46.0	Refractory anemia without ring sideroblasts, so stated
D46.4	Refractory anemia, unspecified
D46.a	Refractory cytopenia with multilineage dysplasia

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

D46.b	Refractory cytopenia with multilineage dysplasia and ring sideroblasts
D46.22	Refractory anemia with excess of blasts 2
D46.c	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
D46.9	Myelodysplastic syndrome, unspecified
D46.z	Other myelodysplastic
D47.1	Chronic myeloproliferative disease
D47.z1	Post-transplant lymphoproliferative disorder (PTLD)
C94.41	Acute panmyelosis with myelofibrosis
C94.40	Acute panmyelosis with myelofibrosis not having achieved
C94.42	Acute panmyelosis with myelofibrosis, in relapse
D47.1	Chronic myeloproliferative
C94.6	Myelodysplastic disease, not classified
D47.9	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified
C88.8	Other malignant immunoproliferative diseases
D47.z9	Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and
D48.7	Neoplasm of uncertain behavior of other specified sites
D48.9	Neoplasm of uncertain behavior, unspecified
D69.3	Immune thrombocytopenic purpura
D69.51	Posttransfusion purpura
D69.5	Secondary thrombocytopenia
D69.59	Other secondary thrombocytopenia

*\*If applicable, please see Medicare LCD or NCD for additional covered diagnoses.*

## IX. POLICY HISTORY

MP-2.134	CAC 3/31/09 New Policy
	CAC 3/30/10 Consensus Review
	CAC 4/26/2011 Consensus Review
	CAC 6/26/12 Consensus. Deleted requirement for enrollment in the Risk Evaluation and Mitigation Strategy (REMS) (NEXUS) [Network of Experts Understanding and Supporting) program to track the long-term safety of Nplate therapy. This was indicated in the Description/Background section. No change to policy statements.
	7/26/13 Admin coding review complete--rsb
	CAC 9/24/13 Consensus. No change to policy statements. References updated. Rationale section added. Removed Medicare variation and references as a note

# MEDICAL POLICY



<b>POLICY TITLE</b>	<b>THROMBOPOIETIC GROWTH FACTORS</b>
<b>POLICY NUMBER</b>	<b>MP- 2.134</b>

	only.
--	-------

*Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company<sup>®</sup>, Capital Advantage Assurance Company<sup>®</sup> and Keystone Health Plan<sup>®</sup> Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies*